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ABSTRACT 
 
Hematopoietic malignancies are highly dysregulated processes in which many molecular 
aspects are involved. Long non-coding RNAs (lncRNAs) are increasingly recognized as 
important regulators of gene expression. They are functional RNAs longer than 200 
nucleotides in length, with low coding potential. MIAT was originally identified as a long 
non-coding RNA expressed in neuronal cells and constitutes a component of the nuclear 
scaffold. Moreover it affects the kinetics of the splicing process. Recently, MIAT is 
genetically associated with heart disease. However the molecular basis of MIAT function 
as well as its role in human disease is still in the beginning.  
In the present thesis, Expression of MIAT was studied in leukemic cell lines as well as a large 
cohort of CLL patients. Quantitative analysis of MIAT, revealed extremely MIAT expression 
in B cell lymphoma, while other types of leukemia like AML, ALL and CML did not show 
considerable expression. Feasible prognosis of outcome in CLL sample groups was related to 
MIAT expression. Abundant expression of MIAT achieved in unfavorable outcomes group 
of CLL patient samples (trisomy 12, 17p13 deletion, 11q22 deletion) compared to 
favorable (13q deletion) cytogenetic group. Intriguingly, MIAT expression might be 
associate to aggressiveness and poor outcome in CLL which also empower a role for 
MIAT in leukemia. Since, genetic networks controlling MIAT expression was the focus of our 
intense interest, an association beyond the transcription factors, Oct4, and human MIAT 
transcript was also studied. We showed that mRNA and protein level of Oct4 is in direct 
modulation of MIAT expression in leukemic cell lines as well as CLL patient samples. RNAi 
mediated knockdown of MIAT transcript lead to robust changes in Oct4 mRNA level. We 
further characterized a regulatory feedback loop between Oct4 and MIAT by developing 
lentivirus shRNA to downregulate Oct4 level.  We showed that a reciprocal correlation of 
MIAT and Oct4 regulates their expression. Most importantly, We demonstrated that 
suppression of either Oct4 or MIAT induced apoptosis and reduced viability in lymphoma 
derived cell line. 
In haematological malignancies, More studies on lncRNAs MIAT, may help to identify patient 
populations at risk of leukemia, may classify patients into aggressive or mild cancer groups 
and may also promisingly facilitate the derivation of conventional therapeutic interventions by 
transfering lncRNA research to clinical oncology.  
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CHAPTER 1 : INTRODUCTION 
1.1. Leukemia  
Leukemia  is part of a broader group of neoplasms which affect the blood, bone marrow, 
and lymphoid system, known as tumors of the hematopoietic and lymphoid tissues. 
Leukemia usually begins in the bone marrow and results in high numbers of abnormal white 
blood cells. These white blood cells are not fully developed and are called blasts or leukemia 
cells. WBCs can be formed from different cell lineages, lymphoid or myeloid. In 2012 
leukemia developed in 352,000 people globally and caused 265,000 deaths. 
Both inherited and environmental (non-inherited) factors are believed to be involved (health 
september 2013). Risk factors include smoking, ionizing radiation, some chemicals (such 
as benzene), prior chemotherapy and Down syndrome as well as a family history of 
leukemia. Outcomes have improved in the developed world. The average five-year survival 
rate is 57% in the United States. In children under 15, the five-year survival is greater than 60 
to 85%, depending on the type of leukemia. The cell lineage affected by the cancer determines 
the kind of leukemia and the affect can be sudden or “acute” or can be developing slowly or 
“chronic”. This results in 4 subtypes: acute lymphocytic leukemia (ALL) – most common in 
children, acute myelogenous leukemia(AML,  #1) – most common in adults, chronic 
lymphocytic leukemia (CLL) – most an adult disorder, chronic myelogenous leukemia (CML) 
– most common in adults.  
 
1.1.1. Acute lymphoblastic leukemia (ALL) 
(Incidence, Causes and Risk Factors).  
Acute lymphoblastic leukemia (ALL), results from an acquired or a genetic injury to the 
DNA of a single cell in the marrow. The effects of ALL include uncontrolled and exaggerated 
growth and accumulation of cells called “lymphoblasts” or “leukemic blasts,” which fail to 
function as normal blood cells. The presence of the leukemic blasts blocks the production of 
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normal cells. As a result, when ALL is diagnosed, the number of healthy blood cells (red 
blood cells, white blood cells and platelets) is usually lower than normal(Raetz 2014). (ALL) 
is the most common type of leukemia in young children. ALL occurs most often in the first 
decade of life but increases in frequency again in older individuals. A few factors have been 
associated with an increased risk of developing the disease. Exposure to high doses of 
radiation is one such factor. Also reducing children’s exposure to bacterial infections during 
the first year of  life and multiple diagnostic x-rays during childhood may have increased the 
risk of childhood. Previous chemotherapy and radiation treatment may be a cause of ALL in 
adults(Raetz 2014). Some cases of ALL relate to a mutation in a lymphocyte that occurs 
during the prenatal period (in utero).  
ALL Subtypes: 
ALL Subtypes include precursor B acute lymphoblastic leukemia, precursor T acute 
lymphoblastic leukemia, Burkitt's leukemia, and acute biphenotypic leukemia.  
Immunophenotyping, a process used to identify cells based on the types of proteins (antigens) 
on the cell surface, is necessary to establish the diagnosis of either B-cell ALL, T-cell ALL or 
acute myeloid leukemia (AML,  #2). Mature B-cell leukemia is also known as “Burkitt 
leukemia/lymphoma.” It accounts for 2%-3% of ALL patients. In some studies, ALL has been 
subdivided into CD10 (the common acute lymphoblastic leukemia antigen, abbreviated 
cALLa) positive and CD10 negative. Genetic classification of ALL cells is summarized in 
table 1.1. Translocations are the most common type of DNA change that is associated with 
ALL. In a translocation, the DNA from one chromosome breaks off and becomes attached to a 
different chromosome. Other chromosome changes such as deletions and inversions  can also 
lead to the development of ALL, but these changes are less common. In many cases of ALL, 
the genetic changes are not known(Raetz 2014).  
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Table 1.1: Genetic classification of ALL.   
 
 
  
 
 
 
 
 
 
 
 
 
1.1.2. Acute Myeloid Leukemia (AML) 
AML results from acquired changes in the DNA (genetic material) of a developing marrow 
cell. Once the marrow cell becomes a leukemic cell, it multiplies into 11 billion or more cells. 
These cells, called “leukemic blasts,” do not function normally. However, they grow and 
survive better than normal cells. The presence of the leukemic blasts blocks the production of 
normal cells (Karp 2011). 
(Incidence, Causes and Risk Factors). 
 Most patients diagnosed with AML have no clear-cut triggering event. Repeated exposure to 
the chemical benzene can be a factor in AML development. Benzene damages the DNA of 
normal marrow cells. A small but increasing percentage of AML cases arise following 
treatment with chemotherapy (especially with alkylating agents or topoisomerase II inhibitors) 
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or radiation therapy for other cancers, such as lymphoma, myeloma and breast cancer. But 
only a small proportion of people exposed to chemotherapy, radiation therapy and/or benzene 
develop AML. A theory about why AML develops in some people is that they have inherited 
genes that limit their ability to detoxify the causative agents. (Karp 2011). Genetic disorders, 
such as Fanconi’s anemia, Shwachman syndrome, Diamond-Blackfan syndrome and Down 
syndrome, are also associated with an increased risk of AML. AML may develop from the 
progression of other blood cancers, including polycythemia vera, primary myelofibrosis, 
essential thrombocythemia and myelodysplastic syndromes (MDS) (Karp 2011). AML is the 
most common acute leukemia affecting adults. The risk for developing AML increases about 
10-fold from ages 30 to 34 years (about 1 case per 100,000 people) to ages 65 to 69 years 
(about 10 cases per 100,000 people). For people over 70, the incidence rate continues to 
increase, peaking between the ages of 80 and 84.(Karp 2011). 
AML Subtypes: 
 Most people who are diagnosed with AML have one of the eight AML subtypes shown in 
Table 1.2. This table is based on the French, American, British (FAB) classification system . 
The World Health Organization (WHO) classification system for AML which is based on the 
expected outcomes include : 
AML with recurrent genetic abnormalities ,  AML with myelodysplasia-related changes 
,Therapy-related AML , AML not otherwise specified, AML with a translocation between 
chromosomes 8 and 21, AML with a translocation or inversion in chromosome 16, AML with 
changes in chromosome 11,Acute promyelocytic leukemia (APL, M3), which usually has a 
translocation between chromosomes 15 and 17. (Karp 2011). 
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Table 1.2: Subtypes of AML 
 
 
 
 
 
 
 
 
 
1.1.3. Chronic lymphocytic leukemia (CLL) 
Chronic lymphocytic leukemia (CLL) results from an acquired mutation to the DNA of a 
single marrow cell that develops into a lymphocyte. In 95 percent of people with CLL, the 
change occurs in a B lymphocyte. In the other 5 percent of people with CLL, the cell that 
transforms from normal to leukemic has the features of a T lymphocyte or a natural killer 
(NK) cell. Thus, any of the three major types of lymphocytes (T cells, B cells or NK cells) can 
undergo a malignant transformation that causes diseases related to B-cell CLL. The leukemic 
cells that accumulate in the marrow in people with CLL do not prevent normal blood cell 
production as extensively as is the case with acute lymphoblastic leukemia. This is an 
important distinction: It is the reason for the generally less severe early course of CLL 
comparing to ALL (Byrd 2014). 
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Incidence, Causes and Risk Factors.  
CLL has generally not been associated with any environmental or external factors. First-
degree relatives of patients with CLL are three to four times more likely to develop CLL than 
people who do not have first-degree relatives with the disease. However, the risk is still small. 
The incidence of the disease increases from less than one per 100,000 in individuals aged 40 
to 44 years to more than 30 per 100,000 in individuals aged 80 and older. Older patients tend 
to have a worse outcome due to being diagnosed with a more aggressive CLL and the inability 
to tolerate treatment and symptoms of the disease (Byrd 2014). 
Chromosomal Changes: 
About half of CLL patients who are tested with “G-banding karyotyping” are found to have 
CLL cells with chromosomal abnormalities. About 80 percent of CLL patients who are tested 
with “fluorescence in situ hybridization (FISH)” are found to have chromosomal 
abnormalities. The following examples are some of the more common chromosomal 
abnormalities: 
Del(13q) Deletions on the long arm of chromosome 13, del(13q), are the most common. 
Del(13q) with no other chromosomal abnormalities is associated with a relatively more 
favorable outcome. 
Trisomy 12 About 10 to 20 percent of patients have CLL cells with three copies of 
chromosome 12 (trisomy 12) instead of the expected two chromosomes. Trisomy 12 is 
associated with intermediate-risk CLL. Trisomy 12 with other chromosomal abnormalities is 
associated with a higher risk than trisomy 12 alone. 
Del(11q) Up to 20 percent of people with CLL have deletions in CLL cells in the long arm of 
chromosome 11, del(11q). The proportion of CLL patients with del 11q tend to be younger 
with large lymph nodes and have high-risk disease. 
Chromosome 14 or Chromosome 6 Structural abnormalities of chromosome 14 or 
chromosome 6 in CLL cells indicate higher-risk disease. 
Del(17p) About 5 percent of people with CLL at diagnosis have deletions in the short arm of 
chromosome 17, del(17p). The critical TP53 gene in this region is typically deleted. People 
who have CLL with del(17p) tend to have higher-risk disease and usually do not respond as 
well to standard initial therapy. Their CLL treatment needs to be approached in a different 
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manner. Other factors may be signs of faster-growing disease (higher-risk CLL) and indicate 
the need for closer follow-up with the doctor. For example: 
Blood lymphocyte doubling People with CLL whose lymphocyte number doubles in one year 
have higher-risk CLL and need closer follow up; a lymphocyte number that remains stable 
indicates a relatively lower risk. 
CD38 The expression of CD38 on CLL cells may be an indicator of higher-risk CLL. 
B2M A higher level of serum beta2-microglobulin (B2M), a protein that is shed from CLL 
cells, is associated with a greater extent of disease. Several studies have found that B2M and 
other serum markers, such as CD23, may help predict survival or progression-free survival.  
Un mutated IgHv The un mutated immunoglobulin heavy chain variable region gene (IgHv) 
suggests the likelihood of higher-risk disease. Forty percent of CLL patients at diagnosis will 
have this whereas 60 percent will have the more favorable IgHv-mutated disease. 
ZAP-70 (zeta-associated protein 70), when increased, may be associated with higher-risk 
disease. It should be noted that further study in clinical trials is needed to standardize the 
assessment of ZAP-70. The National Comprehensive Cancer Network (NCCN) guidelines 
state that the evaluation of ZAP-70 expression by flow cytometry can be challenging and is 
not recommended outside of a clinical trial. There are new tests such as ZAP-70 methylation 
which may represent a better way to measure this. Additionally, other prognostic markers such 
as CD49d expression have also been suggested as a better biomarker than ZAP-70 (Byrd 
2014). 
NOTCH1 gene Notch1 is a gene involved in the development of different type of blood cells. 
In CLL, approximately 10 to 15 percent of patients have mutations of this gene causing it to be 
more active than it should be.  
SF3B1 gene This gene is involved in the forming of select proteins in CLL and other blood 
cancers. It is mutated in several blood cancers including CLL, AML, and MDS. In CLL, 
approximately 10 to 15 percent of patients have mutations of this gene, resulting in 
dysfunctional protein processing. Several studies have suggested that CLL patients who have 
SF3B1 gene mutations may progress more quickly, requiring therapy and have a shorter 
remission and overall survival .  
TP53 gene mutations The TP53 gene is viewed as the gatekeeper to protecting the DNA of 
cells from damage. Mutated DNA of cancer cells lead to increased cancer growth and 
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resistance to chemotherapy cancer treatments. Mutation of the TP53 gene is very commonly 
seen in patients who also have del(17p) findings on their interphase cytogenetics. Some 
patients just have mutation of the TP53 gene and, in general, these patients have a higher 
likelihood of progressing more quickly, requiring therapy, not responding well to traditional 
therapies and having an overall shorter survival. Select newer therapies work better for 
patients who have del(17p) or the TP53 gene mutations (Byrd 2014). 
 
1.1.4. Chronic myeloid leukemia (CML) 
CML is a type of cancer that starts in the blood-forming cells of the bone marrow and invades 
the blood. The National Cancer Institute estimates 33,990 people in the United States are 
living with CML, with another 5,980 new cases expected in 2014. Chronic myeloid leukemia 
(CML) is called by several other names, including, Chronic myelogenous leukemia, Chronic 
granulocytic leukemia, Chronic myelocytic leukemia. CML results from an acquired or a 
genetic injury to the DNA of a single bone marrow cell. The mutated cell multiplies into many 
cells (CML cells). CML does not completely interfere with the development of mature red 
cells, white cells and platelets. As a result, chronic phase myeloid leukemia is generally less 
severe than acute leukemia, and often patients do not have any symptoms when diagnosed. 
 
Incidence, Causes and Risk factors:  
Most cases of CML occur in adults. The frequency of CML increases with age, from about 
less than 1.2 in 100,000 people until about 40 years, to about 2.4 in 100,000 people at 55 
years, to about 9.6 in 100,000 people at 80 years and older. No one is born with CML. 
Scientists do not yet understand why the BCR-ABL gene that leads to CML is formed in some 
people and not in others. However, in a small number of patients, CML is caused by exposure 
to very high doses of radiation. This effect has been most carefully studied in the survivors of 
the atomic-bomb blast in Japan. A slight increase in risk also occurs in some individuals 
treated with high-dose radiation therapy for other cancers, such as lymphoma. Most people 
treated for cancer with radiation do not go on to develop CML, and most people who have 
CML have not been exposed to high-dose radiation. Exposures to diagnostic dental or medical 
x-rays have not been associated with an increased risk of CML(Neil P. Shah 2014). 
         CHAPTER1: INTRODUCTION 
 
page9 
 
 
The Philadelphia Chromosome.  
CML was initially distinguished from other types of leukemia by the presence of a genetic 
abnormality of chromosome 22 found in the blood and marrow cells of patients with CML. 
In 1960, doctors from the University of Pennsylvania School of Medicine in Philadelphia 
discovered the 22nd chromosome in people with CML was shorter than it was in healthy 
people. This shortened 22nd chromosome was later named the “Philadelphia chromosome” or 
“Ph chromosome.”Figure 1.1. 
 
 
 
 
 
  
 
 
 
 
 
 
 
Figure1.1 Shown here is the set of chromosomes from a marrow cell of a female patient with CML.The arrow in 
the second row indicates chromosome 9,which is elongated.The arrow in the forth row indicates shortened arm of 
chromosome 22 (the Ph chromosome). 
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The BCR-ABL Cancer-Causing Gene Further studies of CML cells stablished that 
translocation of two chromosomes take place. The translocation of chromosome 9 and 
chromosome 22 is found only in the leukemia cells of CML patients and in some patients with 
acute lymphoblastic leukemia (ALL). One theory that scientists propose about why this switch 
occurs is that when the cells are dividing, chromosomes 9 and 22 are very close to each other, 
making this error more likely. The break on chromosome 9 leads to a mutation of a gene 
called “ABL” (for Herbert Abelson, the scientist who discovered this gene). The break on 
chromosome 22 involves a gene called “BCR” (for breakpoint cluster region). The mutated 
ABL gene moves to chromosome 22 and fuses with the remaining portion of the BCR gene. 
The result of this fusion is the leukemia-causing fusion gene BCR-ABL . Genes provide cells 
with instructions for making proteins. The BCR-ABL gene produces a dysfunctional protein 
called“BCR-ABL tyrosine kinase”. The BCR-ABL tyrosine kinase leads to the abnormal 
regulation of cell growth and survival and is responsible for the development of CML. For that 
reason, the BCR-ABL tyrosine kinase is a target for specific drug therapies that block its 
effects in many people with CML (Neil P. Shah 2014). 
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                Figure 1.2. The process of translocation between the genes on chromosomes 9 and 22 
 
 
 
 
 
 
 
                 Figure 1.3. Leukemia causing process in a Marrow stem cell 
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Diagnosis 
Complete Blood Count (CBC). People with CML often have Decreased hemoglobin 
concentration, Increased white blood cell count, often to very high levels Possible increase or 
decrease in the number of platelets depending on the severity of the person’s CML, Specific 
pattern of white blood cells Small proportion of immature cells (leukemic blast cells and 
promyelocytes) Larger proportion of maturing and fully matured white blood cells 
(myelocytes and neutrophils).  
Bone Marrow Aspiration and Biopsy. These tests are used to examine marrow cells to find 
abnormalities and are generally done at the same time. The sample is usually taken from the 
patient’s hip bone after medicine has been given to numb the skin. Both samples are examined 
under a microscope to look for chromosomal and other cell changes.  
Cytogenetic Analysis. This test measures the number and structure of the chromosomes. 
Samples from the bone marrow are examined to confirm the blood test findings and to see if 
there are chromosomal changes or abnormalities, such as the Philadelphia (Ph) chromosome. 
The presence of the Ph chromosome (the shortened chromosome 22) in the marrow cells, 
along with a high white blood cell count and other characteristic blood and marrow test 
findings, confirms the diagnosis of CML. A small percentage of people with clinical signs of 
CML do not have cytogenetically detectable Ph chromosome, but they almost always test 
positive for the BCR-ABL fusion gene on chromosome 22 with other types of tests. 
FISH (Fluorescence In Situ Hybridization). FISH is a more sensitive method for detecting 
CML than the standard cytogenetic tests that identify the Ph chromosome. FISH is a 
quantitative test that can identify the presence of the BCR-ABL gene . FISH uses color probes 
that bind to DNA to locate the BCR and ABL genes in chromosomes. Both BCR and ABL 
genes are labeled with chemicals each of which releases a different color of light. The color 
shows up on the chromosome that contains the gene— normally chromosome 9 for ABL and 
chromosome 22 for BCR—so FISH can detect the piece of chromosome 9 that has moved to 
chromosome 22 in CML cells. Since this test can detect BCR-ABL in cells found in the blood, 
it can be used to determine if there is a significant decrease in the number of circulating CML 
cells as a result of treatment. 
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                                   Figure 1.4. Identifying the BCR-ABL gene using FISH 
 
Polymerase Chain Reaction (PCR) The BCR-ABL gene is also detectable by molecular 
analysis. Quantitative PCR is used to determine the relative number of cells with the abnormal 
BCR-ABL gene in the blood. This has become the most used and relevant type of PCR test 
because it can measure small amounts of disease, and the test is performed on blood samples, 
so there is no need for a bone marrow biopsy procedure.  
Blood cell counts, bone marrow examinations, FISH and PCR may also be used to track a 
person’s response to therapy once treatment has begun (Neil P. Shah 2014). 
CML-Related Disorders 
There are other subtypes of myeloid leukemia that have a chronic course and have some of the 
signs and symptoms of CML. These include 
Chronic myelomonocytic leukemia (CMML) 
Juvenile myelomonocytic leukemia (JMML) 
Chronic neutrophilic leukemia (CNL). 
These diseases are less common “myeloproliferative neoplasms.” People with these diseases 
do not have the BCR-ABL gene; the absence of the BCR-ABL gene is one of several 
distinguishing features used to make the correct diagnosis. In general, CMML, JMML and 
CNL create more severe changes in blood cell counts early in the course of the disease; these 
changes are not as well controlled with current drug treatments (Neil P. Shah 2014). 
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Other subtypes of Leukemia: 
Hairy cell leukemia (HCL) is sometimes considered a subset of chronic lymphocytic 
leukemia, but does not fit neatly into this pattern. About 80% of affected people are adult men. 
No cases in children have been reported. HCL is incurable, but easily treatable. Survival is 
96% to 100% at ten years.(Else, Ruchlemer et al. 2005)  
T-cell prolymphocytic leukemia (T-PLL) is a very rare and aggressive leukemia affecting 
adults; somewhat more men than women are diagnosed with this disease.(Matutes 1998) 
Despite its overall rarity, it is also the most common type of mature T 
cell leukemia;(Valbuena, Herling et al. 2005) nearly all other leukemias involve B cells. 
Large granular lymphocytic leukemia may involve either T-cells or NK cells; like hairy cell 
leukemia, which involves solely B cells, it is a rare and indolent leukemia.  
Adult T-cell leukemia is caused by human T-lymphotropic virus (HTLV), Like HIV, 
HTLV infects CD4+ T-cells and replicates within them; however, unlike HIV, it does not 
destroy them. Instead, HTLV "immortalizes" the infected T-cells, giving them the ability to 
proliferate abnormally. Human T cell lymphotropic virus types I and II (HTLV-I/II) are 
endemic in certain areas of the world. 
1.1.5.  Lymphoma 
Lymphoma is the name for a group of blood cancers that develop in the lymphatic system. 
Hodgkin lymphoma and non-Hodgkin lymphoma are the two main types. About 90 percent of 
people with lymphoma have non-Hodgkin lymphoma (NHL). The rest have Hodgkin 
lymphoma. The lymphoma cells pile up and form lymphoma cell masses. These masses gather 
in the lymph nodes or other parts of the body. Lymphadenopathy or swelling of lymph nodes 
is the primary presentation in lymphoma. B symptoms (systemic symptoms) can be associated 
with both Hodgkin lymphoma and non-Hodgkin lymphoma. They consist of Fever, Night 
sweats, Weight loss, Loss of appetite or anorexia, Fatigue, Respiratory distress or dyspnea, 
Itching(Walter 2013). 
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WHO classification 
The current accepted definition, the WHO classification published in 2001 and updated in 
2008 is the latest classification of lymphoma and is based upon the foundations laid within the 
"Revised European-American Lymphoma classification" (Djebali, Davis et al.). This system 
attempts to group lymphomas by cell type (i.e. the normal cell type that most resembles the 
tumor) and defining phenotypic, molecular, or cytogenetic characteristics.  
Hodgkin Lymphoma 
Hodgkin lymphoma (HL), one of the most curable forms of cancer, was named for Thomas 
Hodgkin, a British pathologist, In 1832. It was officially renamed “Hodgkin lymphoma” in the 
late 20th century when it became evident that the disease results from an injury to the DNA of 
a lymphocyte . The damage to the DNA is acquired rather than inherited. The altered DNA in 
the lymphocyte produces a cancerous change that—if untreated—results in the uncontrolled 
growth of the cancerous lymphocytes. The accumulation of the cancerous lymphocytes results 
in the tumor masses that are found in the lymph nodes and other sites in the body(Carla Casulo 
2013). HL is distinguished from other types of lymphoma by the presence of “Reed-Sternberg 
cells”. Reed-Sternberg cells are usually B cells and have differences and variations to them.  
Incidence, Causes and Risk Factors 
HL is most likely to be diagnosed in people in their 20s or early 30s. It is less common in 
middle age but becomes more common again after age 65. The following are examples of risk 
factors. 
Patients who have a history of a blood test confirming mononucleosis have a 3-fold increased 
risk of HL compared to the general population. People infected with human T-cell 
lymphocytotropic virus (HTLV) or human immunodeficiency virus (HIV) also have increased 
probability of developing HL.  
There are occasional cases of familial clustering, as with many cancers, and there is an 
increase in the incidence of HL in siblings of patients with the disease. These cases are 
uncommon, but the concept of genetic predisposition is under study to determine its role in the 
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sporadic occurrence of HL in otherwise healthy individuals.  Epstein-Barr virus has been 
associated with nearly half of all cases. However, this virus has not been conclusively 
established as a cause of HL(Carla Casulo 2013). 
Diagnosis 
Imaging: The imaging test(s) may show enlarged lymph nodes in the chest or abdomen or 
both. Tumor masses can also occur outside the lymph nodes in lung, bone or other body tissue.  
Lymph node biopsy: HL can be confused with various types of non-Hodgkin lymphoma—
since the treatment is different, a precise diagnosis is needed. A biopsy of an involved lymph 
node or other tumor site is needed to confirm the diagnosis of HL. A needle biopsy of the 
lymph node is usually not sufficient to make a firm diagnosis.   
Immunophenotyping:“immunophenotyping” is sometimes used to distinguish HL from other 
types of lymphoma or other noncancerous conditions. The presence of Reed-Sternberg and 
Hodgkin cells can confirm a diagnosis of HL.(Carla Casulo 2013). 
Subtypes of Hodgkin Lymphoma 
There are two main HL subtypes: 
 Classical Hodgkin lymphoma 
 Nodular lymphocyte-predominant Hodgkin lymphoma.  
 About 95 percent of HL patients have the classical subtype.  
Classical Hodgkin Lymphoma: Classical HL can be further subdivided. Four major subtypes 
have been identified. 
Nodular Sclerosis.  
Mixed Cellularity.  
Lymphocyte-Depleted.  
Lymphocyte-Rich Classical. 
 
Nodular Lymphocyte-Predominant Hodgkin Lymphoma. The cells in NLPHL, known as 
“lymphocytic” and “histolytic” cells, are different from classic Reed-Sternberg B cells. 
Patients with this subtype may have no symptoms and are usually diagnosed with very limited 
disease. It is most common in young men. The NLPHL subtype is indolent and is associated 
with long-term survival (Carla Casulo 2013). 
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 Non-Hodgkin Lymphoma: 
Non-Hodgkin lymphoma (NHL) is the term used for a diverse group of blood cancers that 
share a single characteristic. They arise from an injury to the DNA of a lymphocyte parent 
cell. NHL generally develops in the lymph nodes or in lymphatic tissue found in organs such 
as the stomach, intestines or skin. The REAL/WHO (Revised European-American 
Lymphoma/World Health Organization) classification categorizes subtypes by the appearance 
of the lymphoma cells, the presence of proteins on the surface of the cells and genetic features. 
Follicular lymphoma and diffuse large B-cell lymphoma are the two most common types 
and together account for about 53 percent of cases. Lymphocytic or lymphoblastic leukemias 
and lymphomas are closely related. A cancer that originates in the lymphatic tissue in the 
marrow is designated “lymphocytic leukemia” or “lymphoblastic leukemia”; the acute and 
chronic forms of lymphocytic or lymphoblastic leukemia are the two major examples of this 
type of blood cancer. A cancer that begins in a lymph node or other lymphatic structure in the 
skin, the gastrointestinal tract or another site in the body is called a “lymphoma”(Carla Casulo 
2013) .
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Table 1.3. Diagnostic Designations for Non Hodgkin Lymphoma 
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Incidence, Causes and Risk Factors 
About 69,740 cases of non-Hodgkin lymphoma are expected to be diagnosed in the United 
States in 2013 (Surveillance, Epidemiology, and End Results [SEER] Program; National 
Cancer Institute, 2013). The incidence of NHL increases with age. In the 20- to 24-year 
age-group, 2.5 cases occur per 100,000 persons. The rate increases almost 20-fold to 44.6 
cases per 100,000 individuals by age 60 to 64 years, and over 40-fold to more than 100 
cases per 100,000 persons after age 75. While NHL is between 50 and 100 times more 
prevalent among people with HIV/AIDS than among uninfected individuals, newer 
therapies for HIV infection have lowered the incidence of AIDS-related lymphoma.There 
is  a higher incidence of NHL in farming communities. Studies suggest that specific 
ingredients in herbicides and pesticides such as organochlorine, organophosphate and 
phenoxy acid compounds are linked to lymphoma (Carla Casulo 2013). Exposure to 
certain viruses and bacteria is associated with NHL. It is thought that infection with a virus 
or bacterium can lead to intense lymphoid cell proliferation, increasing the probability of a 
cancer-causing event in a cell. for examples, Epstein-Barr virus (EBV) infection—in 
patients from specific geographic regions—is strongly associated with African Burkitt 
lymphoma. The role of the virus is unclear, since African Burkitt lymphoma also occurs 
among people who have not been infected with EBV. Epstein-Barr virus infection may 
play a role in the increased risk of NHL in persons whose immune systems are suppressed 
as a result of organ transplantation and its associated therapy. Human T-lymphotropic virus 
(HTLV) is associated with a type of T-cell lymphoma in patients from certain geographic 
regions in southern Japan, the Caribbean, South America and Africa. The bacterium 
Helicobacter pylori causes ulcers in the stomach and is associated with the development of 
mucosa-associated lymphoid tissue (MALT) lymphoma in the stomach wall. About a 
dozen inherited syndromes can predispose individuals to later development of NHL. 
Having autoimmune diseases such as Sjögren’s syndrome, lupus, or rheumatoid arthritis, 
may also increase a person’s risk of developing lymphoma (Carla Casulo 2013). 
Diagnosis 
A diagnosis of NHL is usually made by examining a lymph node biopsy specimen. the 
examination includes tests called “immunophenotyping” and “cytogenetic analysis.”  
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Lymph Node Biopsy: Non-Hodgkin lymphoma can involve parts of the body that do not 
involve lymph nodes. When lymphoma is detected exclusively outside of the lymph nodes, 
it is called “primary extranodal lymphoma,” and the biopsy specimen is taken from the 
involved tissue, such as the lung or bone (Carla Casulo 2013). 
Staging 
A physical examination, and the findings from imaging tests, computed tomography (CT) 
scans, tissue biopsies and blood tests are used to determine the extent of the patient’s NHL. 
This process is called “staging,” and the information is used to determine appropriate 
treatments (chemotherapy, radiation). FDG-PET scanning differs from x-rays, CT, MRI 
and ultrasonography, which only provide anatomical images; FDG-PET also measures 
altered tissue metabolism (activity). This imaging technique relies on a radioactive tracer 
called “FDG ([18F]-fluorodeoxyglucose).” FDG is a special form of glucose. The 
radioactive tracer is given intravenously to the patient and enters the cells. Cancer cells 
have a greater attraction to this glucose than normal cells, so cancer cells trap more of the 
radioactive tracer; then the local tracer concentration is measured. This technique allows 
the cancer cells to be separated from normal cells. Using FDG-PET to measure increased 
FDG uptake in lymphoma cells may provide a very sensitive and relatively rapid 
assessment of the lymphoma cells’ response to therapy. 
Blood and Marrow Tests. Blood tests determine whether lymphoma cells are present in 
the blood and if the immunoglobulins made by lymphocytes are deficient or abnormal. 
Check indicators of disease severity such as blood protein levels, uric acid levels and 
erythrocyte sedimentation rate (ESR). Assess kidney and liver functions and hepatitis A, 
hepatitis B and hepatitis C status. Measure two important biological markers, lactate 
dehydrogenase (LDH) and beta2-microglobulin, which are helpful prognostic indicators 
for several NHL subtypes. 
Most patients diagnosed with NHL will have a bone marrow biopsy to make sure there is 
no spread of the disease to the bone marrow and to evaluate the use of specific therapies 
including radioimmunotherapy (Carla Casulo 2013). 
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1.2. Non coding RNA 
Transcriptome analysis by tiling arrays and RNA sequencing has led to the amazing 
conclusion that while 70%–90% of the genome is transcribed, only 2% is dedicated to the 
transcription of protein coding sequences(Mattick 2001). This result has caused a great 
impression in a scientific community that is deeply proteocentric, i.e., is dedicated to the 
study of proteins and generally does not pay much attention to other molecules such as 
lipids or RNAs. 
Most cellular RNA is composed of highly expressed non-coding RNAs whose relevance in 
cell functionality has been well-known for years. However, their transcription requires a 
relatively small proportion of the genome. These housekeeping non-coding RNAs include 
transfer RNAs (tRNAs) and ribosomal RNAs (rRNAs), required for mRNA translation; 
small nuclear RNAs (snRNAs), essential for splicing; and small nucleolar RNAs 
(snoRNAs), involved in RNA modification. More recently, several small RNAs have been 
described as playing essential roles in gene expression and transposon silencing. These 
include microRNAs (miRNAs), small interfering RNAs (siRNAs) and piwi interacting 
RNAs (piRNAs). Less clear is the role and the molecular mechanisms involved in the 
function of other small RNAs derived from retrotransposons or 3' untranslated regions or 
associated with transcription start sites, promoters, termini or repeats. All these non-coding 
RNAs, with the exception of some of the housekeeping RNAs (some rRNAs and a few 
snRNAs and snoRNAs), share the common characteristic of being smaller than 200 nts. 
Therefore the remaining non-coding RNAs, longer than 200 nts, have been grouped under 
the name of long non-coding RNAs (lncRNAs). 
LncRNAs are not really long, just longer than the limit of 200 nts imposed by small RNAs. 
In fact, the average size of coding mRNAs is near 2500 nts while the average length of all 
the lncRNAs recently described by the Encode project is less than 600 nts(Dunham and 
Frietze 2012). Thus, most of the long non-coding RNAs are shorter than the coding 
mRNAs, even if some of the lncRNAs may be longer than 100 kbs. Apart from not being 
really long, it is difficult to determine whether lncRNAs are indeed non-coding. 
Traditionally, lncRNAs have been characterized by what they do not have: they lack open 
reading frames (ORFs) longer than 100 amino acids, conserved codons and homology to 
protein databases (Lin, Carlson et al. 2007),(Lin, Deoras et al. 2008). Therefore, they have 
poor coding potential, although they could still code for small open reading frames or non-
conserved peptides. Some authors have also analyzed coding capacities of specific 
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lncRNAs by matching their sequences with ribosome footprints or peptide fragments from 
mass spectrometry analysis. Hits would indicate translation(Pueyo and Couso 
2011),(Ingolia, Lareau et al. 2011),(Banfai, Jia et al. 2012),(Derrien, Johnson et al. 2012). 
In spite of these efforts, it should be borne in mind that what makes lncRNAs interesting 
for most scientists is not whether they can encode for proteins or not but the fact that they 
are functional as RNA molecules. The demonstration of function as an RNA should be 
required for annotation as an lncRNA, as a functional long RNA is the best definition for 
lncRNAs. To complicate things further, there are several cases of coding mRNAs that 
contain regulatory RNA elements and act as bifunctional RNAs; on one hand they code for 
a protein (p53, for instance) and on the other hand they have a function asRNAs(Kloc, 
Wilk et al. 2005),(Wadler and Vanderpool 2007),(Dinger, Pang et al. 2008),(Leygue 
2007),(Jenny, Hachet et al. 2006),(Candeias, Malbert-Colas et al. 2008). Furthermore, 
several coding genes are transcribed to non-coding alternative splicing variants. Functional 
or lncRNA genes are very similar to coding genes at the DNA and chromatin level as they 
share the same epigenetic marks. Similar to mRNAs, most lncRNAs are transcribed from 
RNA polymerase II, are capped at the 5' end, contain introns and approximately 40% are 
polyadenylated at the 3' end(Guttman, Amit et al. 2009). The lncRNAs recently described 
by Encode show a bias for having just one intron and a trend for less-efficient 
cotranscriptional splicing(Derrien, Johnson et al. 2012),(Kloc, Wilk et al. 2005),(Wadler 
and Vanderpool 2007),(Dinger, Pang et al. 2008),(Leygue 2007),(Jenny, Hachet et al. 
2006),(Candeias, Malbert-Colas et al. 2008),(Guttman, Amit et al. 2009),(Tilgner, 
Knowles et al. 2012). It has been estimated that there could be as many lncRNA genes as 
coding genes, but the number of lncRNAs is still growing and some authors consider that it 
could increase from ~20,000 to ~200,000(Gibb, Vucic et al. 2011),(Mercer, Dinger et al. 
2008). Compared to mRNAs, most lncRNAs localize preferentially to the nucleus, are 
more cell type specific and are expressed at lower levels(Djebali, Davis et al. 2012). In 
fact, there is less than one copy per cell of many lncRNAs. The low expression levels and 
the fact that the sequence of lncRNAs is poorly conserved have convinced many scientists 
that they are not relevant for cell functionality. However, although lncRNAs are under 
lower selective pressure than protein-coding genes, sequence analysis shows that lncRNAs 
are under higher selective pressure than ancestral repeat sequences with neutral selection. 
Moreover, promoters of lncRNAs have similar selection levels than promoters of protein 
coding genes(Derrien, Johnson et al. 2012). Even in the absence of strong sequence 
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conservation, the genomic location and structure of many lncRNAs is conserved together 
with short stretches of sequences, suggesting that lncRNAs could be under selective 
pressure to maintain a functional RNA structure rather than a linear sequence(Derrien, 
Johnson et al. 2012). Recent publications in the field have led to the hypothesis that many 
lncRNAs may be key regulators of development and may play relevant roles in cell 
homeostasis and proliferation. In fact, several lncRNAs have been described that function 
as oncogenes or tumor suppressors(Hauptman and Glavac 2013). It is expected that for cell 
biology the role of lncRNAs could be as revolutionary as the role of small non-coding 
RNAs such as miRNAs. miRNA studies have highlighted the relevance of gene regulation 
in cell homeostasis, differentiation and proliferation and may impact the clinic with new 
therapies and new diagnostic and prognostic tools for many diseases. The relevance of 
miRNAs has been clearly established for haematological malignancies(Agirre, Jimenez-
Velasco et al. 2008),(Agirre, Vilas-Zornoza et al. 2009).  
 
1.2.1. Classes of lncRNAs and lncRNA Functionality 
 
Classification by Genomic Location 
Under the name of lncRNAs there are RNAs with many different characteristics, which 
complicates classification. Therefore a well accepted method is based on genomic location 
rather than on functionality, conservation or origin. From a genetic point of view lncRNAs 
can be classified into one or more of the following categories:  
(a) sense, when overlapping with one or more exons of another transcript in the same 
strand;  
(b) antisense, when overlapping with one or more exons of another transcript in the 
opposite strand;  
(c) intronic, when derived from an intron of another transcript; 
(d) divergent or bidirectional, when they share a promoter with another transcript in the 
opposite strand and therefore are coregulated;  
(e) intergenic, when they are independent, located in between two other genes. Long 
intergenic non coding RNAs (lincRNAs) are a special class of intergenic lncRNAs whose 
genes have histone mark signatures of active transcription (trimethylation in lysine 4 and 
lysine 36 of histone 3: H3K4m3, H3K36m3)(Huarte, Guttman et al. 2010). 
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In the case of antisense transcripts, classification based on genomic location helps to 
predict functionality. 50%–70% of sense transcripts have natural antisense partners 
(Panzitt, Tschernatsch et al.) (Katayama, Tomaru et al. 2005),(Carninci, Kasukawa et al. 
2005),(Galante, Vidal et al. 2007). NATs are generally involved in the regulation in cis of 
the corresponding sense RNA by mechanisms that act at the transcriptional and post 
transcriptional level. NATs can induce transcriptional interference or recruit chromatin 
modifiers and remodelers to establish a local transcriptionally active or inactive chromatin 
conformation (Yap, Li et al. 2010). NATs can modify processing and induce or reduce the 
expression or the translation of their sense counterpart. Some intronic lncRNAs also 
regulate the expression of their genomic partners. Intronic lncRNAs may be generated by 
stabilization of the intron after splicing of the host gene but, more commonly, they are 
produced from independent transcription (Guil and Esteller 2012). 
 Classification by Specific Characteristics 
Most lncRNAs with special characteristics cannot be easily classified into a single group 
according to genomic location. These include enhancer RNAs (eRNAs), lncRNA-
activating (lncRNA-a) genes, transcribed ultraconserved regions (T-UCRs), pseudogenes, 
telomere-associated ncRNAs (TERRAs), circular RNAs, etc. eRNAs are transcribed by 
RNA polymerase II at active enhancer regions, characterized by H3 Lys4 mono 
methylation or Lys27 acetylation and binding of the regulatory protein p300 (Heintzman, 
Stuart et al. 2007), (Heintzman, Hon et al. 2009), (Visel, Blow et al. 2009), (Kim, Hemberg 
et al. 2010). eRNAs are not polyadenylated. Many are bidirectional and poorly expressed 
(Kim, Hemberg et al. 2010),(Wang, Garcia-Bassets et al. 2011),(De Santa, Barozzi et al. 
2010), but expression of several eRNAs seems to be tightly regulated (Kim, Hemberg et al. 
2010), (Wang, Garcia-Bassets et al. 2011). Although many eRNAs were thought to be by-
products of the presence of RNA pol II in enhancers, recent evidence suggests that some 
may function to control the expression of neighbouring genes (Orom, Derrien et al. 2010). 
LncRNA-a genes generally transcribe intergenic RNAs which are involved in the 
expression of neighbouring genes (Orom, Derrien et al. 2010). Thus, downregulation of the 
lncRNA-a results in downregulation of the neighbour gene. This effect requires expression 
of the Mediator complex and it has been shown that interaction of the lncRNA-a with 
Mediator is required for the upregulation of nearby genes (Lai, Orom et al. 2013). T-UCRs 
and pseudogenes are lncRNAs that share sequence similarity to other mammalian genomes 
or other regions of the same genome, respectively. There are 481 UCRs longer than 200 bp 
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that are absolutely conserved between human, rat, and mouse genomes (Bejerano, Pheasant 
et al. 2004). Pseudogenes originated from duplication of ancestor or parental coding genes 
(duplicated pseudogenes) or through retrotransposition of processed RNAs transcribed 
from ancestor genes (processed pseudogenes). Subsequently, they have lost their coding 
capacity as a result of the accumulation of mutations. When pseudogenes are expressed, 
they may regulate the expression and function of their parental gene by several 
mechanisms (Hirotsune, Yoshida et al. 2003), (Hawkins and Morris 2010). For instance, 
pseudogenes may act as miRNA decoys that lead to increased stability and translation of 
their parental gene (Harrison, Zheng et al. 2005),(Pink, Wicks et al. 2011), (He 2010), 
(Salmena, Poliseno et al. 2011). Circular RNAs, newcomers to the RNA list, can also 
function as RNA decoys (Ledford 2013), (Kosik 2013),(Memczak, Jens et al. 2013).  
Classification as cis or trans-Acting Molecules 
LncRNAs can also be classified according to their functionality as cis and/or trans acting 
molecules (Figure 5). Trans-acting lncRNAs function away from the site of synthesis while 
cis-acting lncRNAs function at the site of transcription to affect the expression of 
neighbouring genes. Several cis-acting lncRNAs guide epigenetic regulators to their site of 
transcription while they are being transcribed. Thus, lncRNA transcription is critical and 
rapidly creates an anchor to recruit proteins involved in chromatin re modeling (Chu, Qu et 
al. 2011), (Gabory, Jammes et al. 2010), (Mancini-Dinardo, Steele et al. 2006),(Pauler, 
Koerner et al. 2007). This molecular mechanism has tremendous advantages: (i) it 
responds very fast, as it only requires transcription of an RNA and a proper accumulation 
of nuclear chromatin remodelers; (ii) it is very specific, as the targeting does not involve 
RNA-DNA interactions other than those required for lncRNA transcription and (iii) it may 
function with just a single molecule of lncRNA per locus. This may explain the low 
abundance of cis-acting lncRNAs and the relatively high concentration of lncRNAs close 
to developmental genes whose expression is strictly controlled(Engstrom, Suzuki et al. 
2006). Thus, cis-acting lncRNAs control the epigenetic regulation of some imprinted 
genes. Imprinting depends on the parental origin of the imprinted genes, which play critical 
roles in mammalian development and therefore, their expression must be tightly regulated 
(Li and Sasaki 2011). Many imprinted gene loci express lncRNAs that appear to regulate 
the expression of neighbouring imprinted protein-coding genes in cis, allele specifically 
(Mohammad, Mondal et al. 2009). 
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Figure 1.5. Schematic representation of cis and trans-acting lncRNAs. cis-acting lncRNAs function 
at the site of transcription and affect the expression of neighbouring genes.Trans-acting lncRNAs 
function away from the site of synthesis. 
 
 
Trans-acting lncRNAs regulate gene expression on a genome-wide scale. A good example 
is HOTAIR, which binds the chromatin-modifying complexes PRC2, LSD1 and 
CoREST/REST (Khalil, Guttman et al. 2009), (Rinn, Kertesz et al. 2007), (Gupta, Shah et 
al. 2010), (Tsai, Manor et al. 2010). 
1.2.2. lncRNA Functionality 
 
Guiding chromatin remodeling factors seems to be the predominant function exerted by 
lncRNAs. In fact, it has been estimated that 20% of all lncRNAs may bind PRC2 (Khalil, 
Guttman et al. 2009). Several lncRNAs have also been shown to bind to PRC1, 
the CoREST/REST repressor complex (Khalil, Guttman et al. 2009), the histone  ethyl 
transferase associated with the activating trithorax complex, MLL1 (Bertani, Sauer et al. 
2011), (Dinger, Amaral et al. 2008) and H3-K9 methyltransferase, G9a (Nagano, Mitchell 
et al. 2008), (Pandey, Mondal et al. 2008). However, lncRNAs have also been shown to 
exert several other functions in the cell nucleus and cytoplasm, including regulation of 
DNA bending and insulation, RNA transcription, splicing, translation and stability, 
organization of subnuclear structures and protein localization, among others. 
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DNA looping  CTCF can induce chromosomal bending and protect specific genes from the 
effects of distal enhancers and regulatory elements. The lncRNA SRA can interact with and 
enhance the function of CTCF (Yao, Brick et al. 2010). Also, endogenous but not 
exogenous nascent HOTTIP lncRNA, binds target genes via chromosomal looping (Wang, 
Yang et al. 2011).  
Transcription  LncRNAs may activate or inhibit transcription of specific targets. Some 
lncRNAs act as co activators that bind transcription factors and enhance their 
transcriptional activity (Feng, Bi et al. 2006),(Lanz, McKenna et al. 1999), (Caretti, Schiltz 
et al. 2006).This is the function of SRA lncRNA in the progestin steroid hormone receptor 
(Watanabe, Yanagisawa et al. 2001), (Lanz, Chua et al. 2003). However, some lncRNAs 
act as decoys of transcription factors (Kino, Hurt et al. 2010) and may move them to the 
cytoplasm to keep them away from their nuclear targets (Willingham, Orth et al. 2005). 
Thus, p53-induced lncRNA PANDA binds transcription factor NF-YA and prevents NF-
YA activation of cell death genes (Hung, Wang et al. 2011). Finally, the act of lncRNA 
transcription may interfere with transcription initiation, elongation or termination of 
another sense or antisense gene (Mazo, Hodgson et al. 2007). Transcriptional interference 
can also lead to activation of gene expression by inhibiting the action of repressor 
elements.  
Organization of subnuclear structures  LncRNAs can recruit protein factors to nuclear 
structures. This is the case of lncRNA MALAT1 and NEAT-1. MALAT1 recruits 
serine/arginine–rich splicing factors to nuclear speckles (Tripathi, Ellis et al. 2010). More 
importantly, NEAT-1 is an essential structural component of paraspeckles, subnuclear 
structure implicated in RNA splicing and editing (Mao, Sunwoo et al. 2011), (Bond and 
Fox 2009). Depletion of NEAT-1 leads to loss of paraspeckles while overexpression of 
NEAT-1 causes an increase in the number of paraspeckles (Clemson, Hutchinson et al. 
2009), (Chen and Carmichael 2009), (Sunwoo, Dinger et al. 2009). MALAT1 and NEAT-1 
are genomic neighbors over expressed in several tumors compared to healthy tissues. 
Surprisingly the mouse knockouts of either NEAT-1 or MALAT1 had no detectable 
phenotype, suggesting that there could be redundant or compensatory molecules 
(Eissmann, Gutschner et al. 2012), (Ip and Nakagawa 2012), (Nakagawa, Naganuma et al. 
2011), (Zhang, Arun et al. 2012).  
Splicing  Splicing can be inhibited by lncRNAs antisense to intron sequences that impede 
spliceosome binding causing intron retention (Annilo, Kepp et al. 2009), (Allo, Buggiano 
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et al. 2009),(Hastings, Milcarek et al. 1997), (Krystal, Armstrong et al. 1990), (Yan, Hong 
et al. 2005). Furthermore, alternative splicing can be altered by lncRNA-mediated 
sequestration or modification of splicing factors. Thus, MALAT1 binds splicing factors 
present in nuclear speckles and modulates the activity of SR proteins, involved in the 
selection of splice sites, and therefore regulates the splicing of many pre-mRNAs (Tripathi, 
Ellis et al. 2010). Some snoRNA-containing lncRNAs (sno-lncRNAs) are retained close to 
their sites of transcription where the splicing factor Fox2 is enriched. Changes in the level 
of the sno-lncRNA lead to a nuclear redistribution of Fox2 and to changes in alternative 
splicing. Thus, the sno-lncRNAs could function as a regulator of splicing in specific 
subnuclear domains (Yin, Yang et al. 2012). 
Translation  LncRNAs have been described that increase or inhibit translation of specific 
targets (Carrieri, Cimatti et al. 2012), (Yoon, Abdelmohsen et al. 2012).  
Stability  LncRNAs have been described that increase or decrease stability of specific 
targets(Kretz, Siprashvili et al. 2013), (Gong and Maquat 2011). Binding of lncRNAs 
containing ancestral Alu repeats to complementary Alu sequences in the 3´UTR of coding 
mRNAs forms a dsRNA recognized by the dsRNA binding protein Stau1, which induces 
Stau-mediated RNA decay (Gong and Maquat 2011). Instead, lncRNA TINCR localizes to 
the cytoplasm, where it interacts with Stau1 and promotes the stability of mRNAs 
containing the TINCR box motif (Kretz, Siprashvili et al. 2013).  
miRNA binding  LncRNAs can regulate mRNA stability and translation by binding to 
miRNAs and preventing their action. Besides the already described role of some 
pseudogenes and circular lncRNAs in miRNA sequestration, other lncRNAs such as linc-
MD1, have been shown to serve as “sponge” for miRNAs. Linc-MD1 binds two miRNAs, 
which downregulate transcription factors involved in muscle differentiation and therefore 
muscle differentiation is induced upon Linc-MD1 expression (Cesana, Cacchiarelli et al. 
2011). To date few lncRNAs have been described to have catalytic properties. The high 
number of lncRNAs and their heterogeneity helps them to exert such a myriad of 
functions. In fact, all lncRNA functions respond to just three different mechanisms: 
decoys, scaffolds and guides (Ma, Hao et al. 2012). Decoy-acting lncRNAs impede the 
access of proteins such as transcription factors and RNAs such as miRNAs to their targets. 
LncRNAs MD-1 and PANDA act as decoys for miRNAs and transcription factors, 
respectively (Hung, Wang et al. 2011), (Cesana, Cacchiarelli et al. 2011). Scaffold-acting 
lncRNAs serve as adaptors to bring two or more factors into discrete ribonucleoproteins 
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(RNPs) (Spitale, Tsai et al. 2011). LncRNA TERC, HOTAIR or NEAT-1 act as scaffolds to 
form the telomerase complex (Zappulla and Cech 2006), a silencing complex (Tsai, Manor 
et al. 2010) or the paraspeckle, respectively (Mao, Sunwoo et al. 2011), (Bond and Fox 
2009). Guide-acting lncRNAs are required to localize protein complexes at specific 
positions. XIST or AIR lncRNAs act as guides to target gene silencing activity in an allele-
specific manner. In many cases though, the secondary and tertiary structure of lncRNAs 
dictates their function. Thus, lncRNAs generally have complex structures with higher 
folding energies than those observed in mRNAs (Kertesz, Wan et al. 2010). Proteins are 
expected to be the major partners of lncRNAs to form functional RNP particles. RNA 
binding proteins represent more than 15% of the total amount of proteins (Castello, Fischer 
et al. 2012). In several cases studied to date, interaction between proteins and RNAs results 
in conformational changes to the protein, the RNA or both, which could endow the 
complex with a novel ability. LncRNA function impacts cell behaviour. LncRNAs have 
specially emerged as regulators of development. Some transcription factors involved in 
pluripotency bind promoter regions of more than 100 mouse lncRNAs (Guttman, Amit et 
al. 2009). 26 lincRNAs have already been described as being required for the maintenance 
of pluripotency in mouse (Guttman, Donaghey et al. 2011). Two lncRNAs regulated by 
pluripotency transcription factors such as Oct4 and Nanog are essential for pluripotency 
maintenance, as they, in turn, control the expression of Oct4 and Nanog (Sheik Mohamed, 
Gaughwin et al. 2010). Therefore, these lncRNAs participate in positive regulatory loops. 
Similarly, several lncRNAs have been implicated in human disease, including several 
cancers (Taft, Pang et al. 2010). Dysregulated lncRNAs have been described in heart 
disease, Alzheimer disease, psoriasis, spinocerebellar ataxia and fragile X syndrome 
(Faghihi, Modarresi et al. 2008), (Ishii, Ozaki et al. 2006), (Pasmant, Laurendeau et al. 
2007), (Sonkoly, Bata-Csorgo et al. 2005), (Daughters, Tuttle et al. 2009), (Khalil, Faghihi 
et al. 2008), and in several tumors including breast, brain, lung, colorectal, prostate and 
liver cancers, melanoma, leukaemia and others (Calin, Liu et al. 2007), (Gupta, Shah et al. 
2010), (Taft, Pang et al. 2010), (Kogo, Shimamura et al. 2011), (Chung, Nakagawa et al. 
2011), (Yang, Zhou et al. 2011), (Lai, Yang et al. 2012), (Calin, Pekarsky et al. 2007), 
(Khaitan, Dinger et al. 2011), (Huarte and Rinn 2010). LncRNAs have been described that 
function as oncogenes (Li, Feng et al. 2009), tumor suppressors (Huarte, Guttman et al. 
2010), (Yu, Gius et al. 2008) or drivers of metastatic transformation, such as HOTAIR in 
         CHAPTER1: INTRODUCTION 
 
page30 
 
breast cancer (Gupta, Shah et al. 2010). In this study we will concentrate on those 
lncRNAs whose expression is altered in haematological malignancies. 
 
1.2.3. LncRNAs Deregulated in Haematological Malignancies 
 
The impact of non-coding RNAs on haematological malignancies has been well described 
for microRNAs (Lawrie 2013), (Agirre, Martinez-Climent et al. 2012). The list of 
lncRNAs involved in the initiation and progression of blood tumors is still very short and 
expected to grow exponentially in the near future. Some of the lncRNAs that play a role in 
haematological malignancies are in fact host genes of miRNAs with oncogenic or tumor 
suppressor properties. Others endow oncogenic or tumor suppressor properties in the long 
non-coding RNA molecule. The mechanism of action of few of them has been studied in 
some detail. 
 
Host Genes of Small RNAs 
BIC and C13ORF25 
Some lncRNAs were described to have oncogenic properties in blood cells before the 
discovery of miRNAs. This is the case of the B cell Integration cluster (Banfai, Jia et al.) or 
host gene mir-155 (MIR155HG. BIC and miR-155 expression is increased in Hodgkin 
lymphoma, Acute Myeloid Leukemia (AML) and Chronic Lymphocytic Leukemia (CLL) 
but it is not detected in healthy samples (Elton, Selemon et al. 2013). Similarly, 
C13ORF25 or host gene mir-17 (MIR17HG) encodes the miR-17-92 cluster and its 
expression is increased in B-cell lymphoma(Ji, Rao et al. 2011), Mantle Cell Lymphoma 
(MCL) (Rinaldi, Poretti et al. 2007) and other tumors (Hayashita, Osada et al. 2005), 
(Humphreys, Cobiac et al. 2013). 
nc886 or vtRNA2-1 
vtRNA2-1, previously known as pre-miR-886, is a short ncRNA suppressed in a wide range 
of cancer cells that inhibits activation of protein kinase R (PKR) (Kunkeaw, Jeon et al. 
2013). vtRNA2-1 could be a tumour suppressor for AML and its role could be mediated by 
PKR. 
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Table 1.4. lncRNAs in hematopoiesis and hematological malignancies.  
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Figure 1.6. Schematic representation of the function of lncRNAs deregulated in haematological 
malignancies. (A) BIC. Myb transcription factor increases the expression of BIC in several 
leukemias and lymphomas. This results in increased levels of miR-155 and miR-155-mediated 
downregulation of several tumor suppressor genes; (B) ANRIL. The INK4 p15INK4b-p14ARF-
p16INK4a cluster transcribes for an antisense transcript named ANRIL; PcG complex (PRC2) is 
targeted to the INK4 locus by ANRIL, and locus expression is inhibited; (C) MEG3. MEG3, 
among other functions, stimulates p53-dependent tumor suppressor pathways by several 
mechanisms. MEG3 down-regulates MDM2 expression, therefore decreasing p53 MDM2-
mediated degradation. MEG3 increases p53 protein levels and stimulates p53-dependent 
transcription. MEG3 enhances p53 binding to some target promoters such as GDF15; (D) GAS5. 
GAS5 binds the DNA binding domain of glucocorticoid receptors (GR) and impedes GR binding to 
DNA and induction of GR-dependent genes such as cIAP2. 
 
 
 PVT1 
It is not clear whether the role of Plasmacytoma variant translocation 1 (PVT1) lncRNA in 
haematological malignancies depends exclusively on being a miRNA host gene. PVT1 is 
overexpressed, compared to healthy tissues, in breast and ovarian cancer, pediatric 
malignant astrocytomas, AML and Hodgkin lymphoma (Guan, Kuo et al. 2007), 
suggesting that PVT1 could be an oncogene. In fact, upregulation of PVT1 contributes to 
tumor survival and chemoresistance (Guan, Kuo et al. 2007), (Palumbo, Boccadoro et al. 
1990), (You, Chang et al. 2011) while its downregulation inhibits cell proliferation and 
induces a strong apoptotic response (Guan, Kuo et al. 2007). 
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1.2.3.1. LncRNAs with Oncogenic Properties 
 
ANRIL or CDKN2B-AS1 
Antisense Non-coding RNA in the INK4 Locus (ANRIL) or CDKN2B-AS1 is transcribed 
antisense to the p15INK4b-p14ARF-p16INK4a cluster, whose members are key effectors 
of oncogene-induced senescence. ANRIL is located in a genetic susceptibility locus (9p21) 
associated with several diseases, including coronary artery disease (Palumbo, Boccadoro et 
al.), atherosclerosis, intracranial aneurysm, type 2 diabetes, and several cancers, such as 
glioma, basal cell carcinoma, nasopharyngeal carcinoma, and breast cancer (Pasmant, 
Sabbagh et al. 2011). Several single nucleotide polymorphisms (SNP) in this locus alter 
ANRIL structure(Burd, Jeck et al. 2010) and ANRIL gene expression (Liu, Sanoff et al. 
2009), (Cunnington, Santibanez Koref et al. 2010), mediating susceptibility to disease. 
There is a statistically significant association between an ANRIL polymorphism and 
Philadelphia positive Acute Lymphoblastic Leukemia (Ph+ ALL) (Iacobucci, Sazzini et al. 
2011). Furthermore, 69% of samples (n = 16) from patients with ALL and AML showed 
relatively increased expression of ANRIL and downregulated p15 compared to controls(Yu, 
Gius et al. 2008). The expression of ANRIL, CBX7, and EZH2 is coordinated and elevated 
in preneoplastic and neoplastic tissues, leading to decreased p16INK4a expression and 
decreased senescence (Yap, Li et al. 2010). 
 
1.2.3.2. LncRNAs with Tumor Suppressor Properties 
 
MEG3 
The maternally expressed gene 3 (MEG3) was the first lncRNA proposed to function as a 
tumor suppressor. MEG3 is a paternally imprinted polyadenylated RNA, expressed in 
many normal human tissues as several alternative splicing variants (Miyoshi, Wagatsuma 
et al. 2000), (Zhang, Zhou et al. 2003). MEG3 expression was decreased compared to 
healthy tissues in various brain cancers (pituitary adenomas, glioma and the majority of 
meningiomas and meningioma cell lines) (Zhang, Gejman et al. 2010), (Gejman, Batista et 
al. 2008), bladder, lung, renal, breast, cervix, colon and prostate cancers and 
haematological malignancies such as MM, AML or myelodysplastic syndromes. 
Surprisingly MEG3 is overexpressed in Wilms tumor and may be increased or decreased in 
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different hepatocellular carcinomas versus healthy livers (Braconi, Kogure et al. 2011). 
MEG3 activates the tumor suppressor protein p53 at different levels. On one hand MEG3 
down-regulates MDM2 expression, therefore decreasing p53 MDM2-mediated 
degradation(Zhou, Zhang et al. 2012). On the other hand, MEG3 significantly increases 
p53 protein levels and stimulates p53-dependent transcription(Benetatos, Vartholomatos et 
al. 2011). Finally, MEG3 enhances p53 binding to some target promoters such as 
GDF15(Zhang, Rice et al. 2010), (Zhou, Zhong et al. 2007; Zhou, Zhang et al. 2012). In 
bladder cancer a negative correlation has been shown between MEG3 expression and 
autophagy (Ying, Huang et al. 2013). 
 
DLEU1 and DLEU2 
Deleted in leukemia 1 (DLEU1) and 2 (DLEU2) are two genes transcribed head to head in 
a 30-kb region located in the long arm of chrormosome 13 (13q14), which is lost in more 
than 50% of patients with CLL and that predicts a poor prognosis(Dal Bo, Rossi et al. 
2011). Recent studies show that DLEU1 and DLEU2 control transcription of their 
neighbouring candidate tumor suppressor genes, which may act as positive regulators of 
NF-kB activity (Garding, Bhattacharya et al. 2013). Increased expression of DLEU2 leads 
to reduced proliferation and clonogenicity (Lerner, Harada et al. 2009). 
 
 
GAS5 
Growth arrest specific 5 (GAS5) is induced under starvation conditions and is highly 
expressed in cells that have arrested growth(Coccia, Cicala et al. 1992), (Mourtada-
Maarabouni, Pickard et al. 2009). GAS5 modulates cell survival and metabolism by 
antagonizing the glucocorticoid receptor (GR)(Kino, Hurt et al. 2010). GAS5 binds the 
DNA binding domain of GRs directly, preventing GRs from binding to DNA, from 
functioning as transcription activators and from reducing cell metabolism(Kino, Hurt et al. 
2010). Expression of GAS5 is sufficient to repress GR-induced genes, such as the cellular 
inhibitor of apoptosis 2 (cIAP2) and sensitizes cells to apoptosis(Kino, Hurt et al. 2010). 
Thus, GAS5 behaves as a tumor suppressor. GAS5 expression is decreased in breast cancer 
and is almost undetectable in growing leukemia cells and increases after density-induced 
cell cycle arrest(Kino, Hurt et al. 2010),(Coccia, Cicala et al. 1992), (Mourtada-
Maarabouni, Pickard et al. 2009). Downregulation of GAS5 by RNA interference protects 
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leukemic and primary human T cells from the anti-proliferative effect of 
rapamycin(Mourtada-Maarabouni, Hasan et al. 2010). 
 
1.2.3.3. LncRNAs with Dual Functions 
H19 
H19 is an imprinted lncRNA located close to the IGF2 gene. H19 is expressed from the 
maternal allele and IGF2 from the paternal allele (Gabory, Jammes et al. 2010),  (Barsyte-
Lovejoy, Lau et al. 2006). A key feature of cancer is the loss of this imprinting, which 
results in the well documented overexpression of H19 in cancers of the colon, liver, breast 
and bladder and in hepatic metastases, compared to healthy tissues (Barsyte-Lovejoy, Lau 
et al. 2006), (Hibi, Nakamura et al. 1996), (Fellig, Ariel et al. 2005), (Matouk, DeGroot et 
al. 2007), (Berteaux, Lottin et al. 2005). Loss of H19 imprinting has been described in 
adult T-cell leukaemia/lymphoma (ATL) (Takeuchi, Hofmann et al. 2007) and decreased 
H19 expression was found in the bone marrow of patients with clinically untreated chronic 
myeloproliferative disorders, including chronic myeloid leukemia (CML), polycythemia 
vera (PV), essential thrombocythemia (ET), primary myelofibrosis (PMF) and chronic 
myelomonocytic leukaemia (CMML)(Nunez, Bashein et al. 2000), (Bock, Schlue et al. 
2003) and AML (Tessema, Langer et al. 2005). H19 can behave as an oncogene or as a 
tumour suppressor(Gabory, Jammes et al. 2010). H19 expression can be activated by the 
oncogene c-Myc(Barsyte-Lovejoy, Lau et al. 2006) and downregulated by the tumor 
suppressor p53(Dugimont, Montpellier et al. 1998), (Farnebo, Bykov et al. 2010). 
 
1.2.4. LncRNAs and Hematopoietic Malignancies 
1.2.4.1. LncRNAs Poorly Characterized in Haematological 
Malignancies 
 
LincRNA-p21: is a p53 activated lncRNA identified in mouse that binds to and guides 
hnRNP K to target genes. LincRNA-p21 bound hnRNP K acts as a transcriptional repressor 
that leads to the induction of apoptosis(Huarte, Guttman et al. 2010). As BCR-ABL1 
stimulates nRNP-K expression and stability and promotes tumor progression, it has been 
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suggested that lincRNA-p21 could play a relevant role in acute or chronic leukemia (Notari, 
Neviani et al. 2006), (Du, Wang et al. 2010). 
TCL6: T cell Leukemia/Lymphoma 6 (TCL6) is transcribed from a locus involved in 
translocations and inversions with T cell receptor (TCR) (Bhagwat and Ramachandran 
1975). These rearrangements in TCR commonly lead to activation of TCL6 lncRNA and 
other oncogenes related to T cell leukemogenesis (Saitou, Sugimoto et al. 2000). 
WT1-AS: is an antisense lncRNA to WT-1, a well-characterized developmental gene that 
is mutated in Wilms’ tumor (WT) and AML. WT1-AS has been shown to regulate WT1 
protein levels. WT1-AS binds the exon 1 of WT1 mRNA in the cytoplasm. It has been 
suggested that the abnormal splicing of WT1-AS in AML could play a role in the 
development of this malignancy(Dallosso, Hancock et al. 2007). 
CRNDE: is overexpressed, compared to healthy tissue, in more than 90% of colorectal 
adenomas tested, but also in hepatocellular, prostate, brain, kidney and pancreas 
carcinomas and different haematological neoplasia such as AML, MM and T cell 
leukemia(Ellis, Molloy et al. 2012).  
RMRP: Ribonuclease mitochondrial RNA processing (RMRP) is a lncRNA mutated in 
Cartilage-Hair Hypoplasia (CHH), an autosomal recessive chondrodysplasia with short 
stature, which entails a high risk of developing Non-Hodgkin lymphoma disease 
(Taskinen, Ranki et al. 2008), (Ridanpaa, van Eenennaam et al. 2001). 
SNHG5: is a precurssor of snoRNAs, involved in diffuse large B-cell lymphoma(Tanaka, 
Satoh et al. 2000). 
HOXA-AS2: In an acute promyelocytic leukemia (APL) cell line, HOXA-AS2 upregulation 
correlated with inhibition of apoptosis. Treatment with all-trans retinoic acid (ATRA) 
blocked the expression of HOXA-AS2 and increased apoptosis of the APL cell line (Zhao, 
Zhang et al. 2013). 
 
1.2.4.2. LncRNAs Involved in Hematopoiesis 
 
The best studied lncRNA in hematopoiesis is HOTAIRM1 (HOX antisense intergenic 
RNA myeloid 1). HOTAIRM1 is as an essential regulator of myeloid cell differentiation 
that locates at the 3' end of the HOXA cluster and controls HOXA1 expression(Zhang, Lian 
et al. 2009). HOXA genes are important transcriptional regulators in normal and malignant 
hematopoiesis and are known to be important for many cancers including leukemias 
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harbouring MLL rearrangements. HOTAIRM1 is expressed specifically in the myeloid 
lineage and is induced during the retinoic acid-driven granulocytic differentiation of the 
NB4 promyelocytic leukaemia cell line and normal human hematopoietic cells. 
Knockdown of HOTAIRM1 affects retinoic acid-induced expression of HOXA1 and 
HOXA4 (but not distal HOXA genes) and attenuates induction of myeloid differentiation 
genes (Zhang, Lian et al. 2009).  
Other lncRNAs involved in hematopoiesis have also been described. EGO (or EGOT in 
human) lncRNA was identified in mouse eosinophil differentiation of CD34+HSCs where 
it stimulated major basic protein and eosinophil-derived neurotoxin mRNA expression 
(Wagner, Christensen et al. 2007).  
The lncRNA PU.1-AS is an antisense transcript of PU.1 that negatively regulates PU.1 
mRNA translation by a mechanism similar to miRNAs (Ebralidze, Guibal et al. 2008). 
PU.1 is a master hematopoietic transcriptional regulator essential for normal hematopoietic 
development and suppression of leukaemia development.  
LincRNA erythroid prosurvival (EPS) is one of the about 400 lncRNAs whose expression 
is modulated during red blood cell formation and is required for differentiation during 
hematopoiesis in mouse(Zhang, Lian et al. 2009), (Wagner, Christensen et al. 2007), (Hu, 
Yuan et al. 2011). EPS is an erythroid-specific lncRNA that represses expression of 
PYCARD, a proapoptotic gene, and therefore inhibits apoptosis(Hu, Yuan et al. 2011), 
(Paralkar and Weiss 2011). EPS is not well conserved among mammals. It is presently 
unclear whether a human version of EPS exists.  
Finally, THY-ncR1 is a thymus-specific lncRNA expressed in cell lines derived from stage 
III immature T cells in which the neighbouring CD1 gene cluster is also specifically 
activated(Aoki, Harashima et al. 2010). 
 
1.2.5. Regulation of the Expression of lncRNAs Involved in 
Haematological Malignancies 
Altered expression of lncRNAs, similar to that of coding genes, can be the result of 
genomic alterations, epigenetic regulation or a change in response to transcription factors 
or stability effectors such as miRNAs. The presence of mutations in the lncRNA primary 
sequence correlates highly with human diseases. In fact, most mutations in the genome 
occur in noncoding regions (Halvorsen, Martin et al. 2010). Mutations can be large or 
small. Large-scale mutations are deletions and amplifications of hundreds of nucleotides 
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and chromosomal translocations occurring at fragile sites. Genome-wide analyses looking 
for fragile sites in lncRNA genes have not yet been performed. However, it is expected that 
lncRNAs will have a clear association with common chromosomal aberrations similar to 
that found for miRNAs in human haematological malignancies and carcinomas (Calin, Liu 
et al. 2007). In fact, several studies have described lncRNAs affected by large scale 
mutations. One of the best examples is ANRIL, affected by a large germline deletion that 
includes the complete INK4/ARF locus. This deletion is associated with hereditary 
cutaneous malignant melanoma and neural system tumors syndrome (Pasmant, Sabbagh et 
al. 2011). DLEU1 and DLEU2 lncRNAs also locate in a region commonly deleted in CLL. 
 Small scale mutations are deletions or insertions of a few nucleotides. The relevance of 
small scale mutations for lncRNAs is obscured by the fact that little is known about the 
relevance of the primary sequence in lncRNA functionality and expression. It is expected 
that small mutations can lead to disease if they affect relevant linear sequences or they alter 
the structure of domains important in lncRNA functionality or accumulation. In fact, 
several disease-associated SNPs have been described as affecting the structure of the 5' and 
3' non-translated regions of coding genes(Halvorsen, Martin et al. 2010). Furthermore, 
GWAS studies have shown that SNPs in noncoding regions are associated with higher 
susceptibility to diverse diseases. Germline and somatic mutations in lncRNA genes have 
been identified in haematological malignancies and colorectal cancers (Wojcik, Rossi et al. 
2010). Genetic aberrations of the GAS5 locus have been found in melanoma, breast and 
prostate cancers (Morrison, Jewell et al. 2007), (Nupponen and Carpten 2001), (Smedley, 
Sidhar et al. 2000). Several lncRNAs are regulated at the transcriptional level. Thus, 
lncRNAs, such as lincRNA-P21, are activated in response to DNA damage by the direct 
binding of the tumour-suppressor protein p53 to the promoter (Huarte, Guttman et al. 
2010). Similarly, the expression of several lincRNAs responds to pluripotency factors or 
oncogenes. Epigenetic modifications are key regulators of lncRNA expression. This has 
been well described for MEG3 and DLEU1/DLEU2. Expression of the MEG3 locus is 
regulated by two regions, which are hypermethylated in several solid tumors leading to 
downregulation of MEG3 expression (Zhang, Zhou et al. 2003), (Kagami, O'Sullivan et al. 
2010), (Astuti, Latif et al. 2005). AML patients with aberrant hypermethylation of the 
MEG3 promoter showed decreased overall survival (Benetatos, Hatzimichael et al. 2010), 
(Khoury, Suarez-Saiz et al. 2010). Thus, MEG3 methylation status may serve as a useful 
biomarker in this leukemia. A similar MEG3 hypermethylation was observed in 35% of the 
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patients with myelodysplastic syndrome, but in this case there was no statistically 
significant correlation between MEG3 hypermethylation and prognosis (Benetatos, 
Hatzimichael et al. 2010). Demethylation correlated with transcriptional deregulation of 
the neighbouring candidate tumour suppressor genes. Finally, the expression of lncRNAs 
can be regulated by miRNAs. Several miRNAs have been described as regulating T-URC 
expression. This has been best described for miR-155, which is overexpressed in CLL 
compared to healthy cells. miR-155 targets T-UCRs both in vitro and in CLL patient 
samples (Calin, Liu et al. 2007). Interestingly, miR-29a has also been shown to regulate 
MEG3 expression in hepatocarcinoma cell lines(Braconi, Kogure et al. 2011). 
 
1.2.6. MIAT (myocardial infarction associated transcript) 
MIAT (myocardial infarction associated transcript), also known as RNCR2 (retinal non-
coding RNA 2) or Gomafu, is a long non-coding RNA. Single nucleotide 
polymorphisms (SNPs) in MIAT are associated with a risk of myocardial infarction.(Ishii, 
Ozaki et al. 2006).  It is expressed in neurons, and located in the nucleus (Sone, Hayashi et 
al. 2007). It plays a role in the regulation of retinal cell fate specification(Rapicavoli, Poth 
et al. 2010). This gene encodes a spliced long non-coding RNA that may constitute a 
component of the nuclear matrix. Altered expression of this locus has been reported to be 
associated with a susceptibility to myocardial infarction. It has also been proposed that 
pathways involving this transcript may contribute to the pathophysiology of schizophrenia. 
A similar gene in mouse has been associated with retinal cell fate determination. 
Alternatively spliced transcript variants have been identified. [provided by RefSeq, Dec 
2014]. 
MIAT transcript escapes from nuclear export, thereby constituting a component of the 
nuclear matrix. Recent studies have revealed that nuclear lncRNAs are essential for the 
maintenance of nuclear structures and can affect pre-mRNA processing and export, thereby 
regulating gene expression(Ip and Nakagawa 2012). It was suggested that the MIAT RNA 
regulates splicing efficiency by changing the local concentration of splicing factors within 
the nucleus. MIAT RNA binds to the SF1 splicing factor through a tandom repeats of 
UACUAAC sequence with a high affinity, which affects the kinetics of the splicing 
process(Ishii, Ozaki et al. 2006). Interestingly, single nucleotide polymorphisms in the 
human homologue of MIAT are associated with an increased risk of myocardial infarction, 
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and thus the gene has been named myocardial infarction associated transcript 
(MIAT)(Tsuiji, Yoshimoto et al. 2011). Recent studies characterized MIAT as a co-
activator of Oct4 in a regulatory feedback loop. Oct4 is considered a master transcription 
factor for pluripotent cell self-renewal. A defined Oct4 level controls the establishment of 
naive pluripotency as well as commitment to all embryonic lineages (Rapicavoli, Poth et 
al. 2010; Sheik Mohamed, Gaughwin et al. 2010; Radzisheuskaya, Chia Gle et al. 2013). 
Cloning and expression 
By screening a human fetal brain cDNA library, followed by 5-prime and 3-prime 
RACE, (Ishii, Ozaki et al. 2006) obtained 4 MIAT splice variants. Northern blot analysis 
detected a 10-kb transcript that was highly expressed in fetal brain and in adult brain and 
spleen. Weaker expression was detected in adult peripheral blood leukocytes, lung, liver, 
thymus, colon, and small intestine. In vitro translation resulted in no protein products, 
suggesting the MIAT variants may function as RNAs. 
Mapping 
By genomic sequence analysis, (Ishii, Ozaki et al. 2006) mapped the MIAT gene to 
chromosome 22q12.1. The MIAT gene is located on the long (q) arm of chromosome 
22 at position 12.1. More precisely, the MIAT gene is located from base pair 26,657,481 to 
base pair 26,676,477 on chromosome 22. 
 
 
 
 
 
Figure 1.7. MIAT gene location on long arm of chromosome 22 
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Molecular Genetics 
(Ishii, Ozaki et al. 2006) performed a case-control association study in 188 Japanese 
myocardial infarction (MI; 608446) patients and 752 controls using 52,608 haplotype-
based SNPs and identified a SNP (rs2301523) on chromosome 22q12.1 that was 
significantly associated with MI (p = 0.0006). Further analysis using a total of 3,464 MI 
patients and 3,819 controls confirmed the association with MI (chi square = 22.71; p = 
0.0000019; odds ratio, 1.36). Following linkage disequilibrium (LD) mapping, haplotype 
analyses revealed that 6 SNPs in this locus, all of which were in complete LD, showed 
markedly significant association with MI.  
In a case-control association study involving 3,464 Japanese myocardial infarction 
(608446) patients and 3,186 controls, (Ishii, Ozaki et al. 2006) identified a 6-SNP 
haplotype block, defined by the SNPs 5338C-T in intron 1, 8813G-A and 9186G-A in exon 
3, and 11093G-A, 11741G-A, and 12311C-T in exon 5 of the MIAT gene, that was 
significantly associated with myocardial infarction (p less than 0.0000030 for each SNP). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.8a. MIAT is located within novel subnuclear domains. It interacts with the 
splicing factor,SF1, and can affect the efficiency of splicing in vitro; therefore it may also 
have the ability to affect splicing in vivo 
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Figure1. 8b. Genomic organization and splicing variant of MIAT. a, Genomic structure of MIAT. 
Base pair numbering at the top was based on an entry from Gene Bank DNA database 
NT011520,10.b, Four splicing variants of MIAT and their possible open reading frames. The 
longest ORF was shown in grey. inverted triangle and vertical line indicate ATG initiation codon 
and stop codon, respectively 
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1.3. Oct4 transcription factor 
 
Oct-4 (octamer-binding transcription factor 4) also known as POU5F1 (POU domain, class 5, 
transcription factor 1) is a protein that in humans is encoded by the POU5F1 gene.(Takeda, Seino 
et al. 1992) Oct-4 is a homeodomain transcription factor of the POU family. This protein is 
critically involved in the self-renewal of undifferentiated embryonic stem cells. As such, it is 
frequently used as a marker for undifferentiated cells. Oct-4 expression must be closely regulated; 
too much or too little will cause differentiation of the cells.(Niwa, Miyazaki et al. 2000). 
The octamer (made of eight units) in this family of transcription factors is the 
DNA nucleotide sequence "ATTTGCAT", the etymology for the naming of the octamer 
transcription factor(Petryniak, Staudt et al. 1990).  
During embryonic development, Oct4 is expressed initially in all blastomeres. Subsequently, its 
expression becomes restricted to the ICM and downregulated in the TE and the primitive endoderm. 
At maturity, Oct4 expression becomes confined exclusively to the developing germ cells (Pesce and 
Scholer 2001),(Pesce and Scholer 2000). Targeted disruption of Oct4 in mice has produced 
embryos devoid of a pluripotent ICM(Nichols, Zevnik et al. 1998), suggesting that Oct4 is required 
for maintaining pluripotency. Furthermore, quantitative analysis of Oct4 expression revealed that a 
high level of Oct4 expression drives ES cells towards the extra-embryonic mesoderm or endoderm 
lineages, while those with a low level of Oct4 become trophectodermal cells; ES cells with a normal 
level of Oct4 remain pluripotent(Niwa 2001)],(Niwa, Miyazaki et al. 2000). Thus, it has been 
proposed that Oct4 is a key regulator of stem cell pluripotency and differentiation(Pesce and 
Scholer 2001),(Pesce and Scholer 2000). Further investigation of Oct4 may help unravel the 
molecular and cellular mechanisms of stem cell pluripotency.  
Expression and Function 
Oct-4 transcription factor is initially active as a maternal factor in the oocyte but remains active in 
embryos throughout the preimplantation period. Oct-4 expression is associated with an 
undifferentiated phenotype and tumors.(Looijenga, Stoop et al. 2003) Gene knockdown of Oct-4 
promotes differentiation, thereby demonstrating a role for these factors in human embryonic stem 
cell self-renewal.(Zaehres, Lensch et al. 2005). Oct-4 can form a heterodimer with Sox2, so that 
these two proteins bind DNA together(Rodda, Chew et al. 2005). Mouse embryos that are Oct-4-
deficient or have low expression levels of Oct-4 fail to form the inner cell mass, lose pluripotency 
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and differentiate into trophectoderm. Therefore, the level of Oct-4 expression in mice is vital for 
regulating pluripotency and early cell differentiation since one of its main functions is to keep the 
embryo from differentiating. 
Implications in disease 
Oct-4 has been implicated in tumorigenesis of adult germ cells. Ectopic expression of the factor in 
adult mice has been found to cause the formation of dysplastic lesions of the skin and intestine. 
The intestinal dysplasia resulted from an increase in progenitor cell population and the upregulation 
of β-catenin transcription through the inhibition of cellular differentiation.(Hochedlinger, Yamada 
et al. 2005).  
Pluripotency in embryo development  
Animal model 
In 2000, Niwa et al. used conditional expression and repression in murine embryonic stem (ES) 
cells to determine requirements for Oct-4 in the maintenance of developmental potency.(Niwa, 
Miyazaki et al. 2000) Although transcriptional determination has usually been considered as a 
binary on-off control system, they found that the precise level of Oct-4 governs 3 distinct fates of 
ES cells. A less-than-2-fold increase in expression causes differentiation into primitive endoderm 
and mesoderm. In contrast, repression of Oct-4 induces loss of pluripotency and dedifferentiation to 
trophectoderm. Thus, a critical amount of Oct-4 is required to sustain stem cell self-renewal, and 
up- or down regulation induces divergent developmental programs. Niwa et al. suggested that their 
findings established a role for Oct-4 as a master regulator of pluripotency that controls lineage 
commitment and illustrated the sophistication of critical transcriptional regulators and the 
consequent importance of quantitative analyzes. The transcription factors Oct-4, Sox2 and Nanog 
are capable of inducing the expression of each other, and are essential for maintaining the self-
renewing undifferentiated state of the inner cell mass of the blastocyst, as well as in embryonic 
stem cells (which are cell lines derived from the inner cell mass).(Rodda, Chew et al. 2005). Oct-4 
is one of the transcription factors used to create induced pluripotent stem cells, together 
with Sox2, Klf4 and often c-Myc in mouse (Okita, Ichisaka et al. 2007),(Wernig, Meissner et al. 
2007),(Maherali, Sridharan et al. 2007) demonstrating its capacity to induce an embryonic stem 
cell-like state. It was later deterimined that only two of these four factors, Oct4 and Klf4 were 
sufficient to reprogram mouse adult neural stem cells. Finally it was shown that a single factor, Oct-
4 was sufficient for this transformation.(Kim, Sebastiano et al. 2009). 
In adult stem cells 
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Several studies suggest a role for Oct-4 in sustaining self-renewal capacity of adult somatic stem 
cells (i.e. stem cells from epithelium, bone marrow, liver, etc.)(Tai, Chang et al. 2005) Other 
scientists have produced evidence to the contrary,(Lengner, Camargo et al. 2007) and dismiss those 
studies as artifacts of in vitro culture, or interpreting background noise as signal,(Lengner, Welstead 
et al. 2008) and warn about Oct-4 pseudogenes giving false detection of Oct-4 
expression.(Zangrossi, Marabese et al. 2007). Oct-4 has also been implicated as a marker of cancer 
stem cells.(Kim and Nam 2011), (Atlasi, Mowla et al. 2007).  
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Fig 1.9. Structure and Function of Oct4 A. a schematic illustration of Oct4 domains. Note the C 
domain behaves differently from the N domain with respect to cell type-specific transactivation. B. The 
upstream regulatory elements of the Oct4 gene. DE, distal enhancer, and PE, proximal enahncer, are 
important for regulating Oct4 expression. There are 4 regions that are highly conserved among human, 
bovine and mouse Oct4 promoter/enhancer elements, shown as green box 1 through 4 relative to DE and PE. 
Conserved region 1 (CR1) is downstream of PE and immediately upstream of exon 1. Each enhancer 
contains multiple potential binding sites for transcription factors that can either activate (red) or repress Oct4 
expression. In addition, methylation in these regions represses Oct4 expression in differentiated cells. 
C.Modes of action of Oct4 on different target genes. Oct4 represses gene expression either indirectly by 
neutralizing activators such as FOXD3 (example 1), or directly by binding to promoters (example 2). Oct4 
also acts as an activator of gene transcription by binding to octamer sites located upstream (example 4 and 5) 
or downstream (example 3) of target genes. In the simplest mode, Oct4 binds to octamer sites immediately 
upstream of the promoter to activate gene expression directly (example 5). Alternatively, Oct4 can synergize 
with other factors like Sox2 to activate gene transcription (example 3). When located at a considerable 
distance, as in example 4, adaptor proteins must be involved to bridge Oct4 to the basic transcription 
machinery for transcriptional activation.  
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Fig 1.10. ES cells and Oct4 expression The isolation and differentiation of ES cells in vitro are illustrated 
schematically starting with the fertilization of an egg by a sperm to form a zygote. At the blastocyst stage, 
inner cell mass (ICM) becomes visible and can be extracted and cultured in vitro to form embryonic stem 
(ES) cells. Cultured ES cells can be induced to differentiate into various cell types that are negative for Oct4. 
The stages of Oct4 expression are noted and the cells with Oct4 expression are marked in red colour. There 
is a general correlation between Oct4 expression and totipotency.(Pan, Chang et al. 2002). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.11. Long non- coding RNA(lncRNA) MIAT localized in pyramidal neurons in the cerebral cortex. 
Green: lncRNA 
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CHAPTER 2: SPECIFIC AIMS OF STUDY 
 
Long non-coding RNAs (lncRNAs) constitute a significant fraction of the transcriptional 
output from the mammalian genome; lacking considerable protein-coding abilities which 
mostly involved in transcriptional and post-transcriptional gene regulation (Ponting, Oliver et 
al. 2009; Lipovich, Johnson et al. 2010; Hu, Alvarez-Dominguez et al. 2012). MIAT (also 
referred to as RNCR2⁄Gomafu) was originally identified as a noncoding RNA which is widely 
and abundantly expressed in the nervous system throughout development, and its expression 
continues into adulthood(Sone, Hayashi et al. 2007). Recent studies have revealed that nuclear 
lncRNAs are essential for the maintenance of nuclear structures and can affect pre-mRNA 
processing and export, thereby regulating gene expression(Ip and Nakagawa 2012). However 
the molecular basis of MIAT function as well as its role in human disease is still in the 
beginning.  
 
We set two major specific aims: 
 
(i) Studying the differential expression of lncRNA MIAT in Leukemic malignancies. 
 
Quantitative Real Time PCR assay employ to established the differential expression of 
MIAT in available number of B and T cell lines derived from all types of leukemia . As 
well, analyzing the expression level of MIAT transcript in a large cohort of patient 
samples, will be done to establish the clinical significance of the dysregulation of MIAT 
non coding RNA in an aggressive form of Leukemia, CLL. Careful analysis of MIAT 
expression in different cytogenetically groups of CLL patient, also provide a guidelines 
to associate the lncRNAs  expression levels with malignancy prognosis as well as 
aggressiveness or even response to treatment. The present study also try to assess the 
effect of the dysregulation of MIAT long non coding RNA in abnormal behavior of 
cancerous cells, as proliferation and apoptosis programmed death.  This would be the 
first study, to our knowledge, where expression of lncRNA MIAT is evaluated in a 
hematopoietic malignancy.  
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(ii) Studying the regulatory correlation of the lncRNA MIAT and the master 
pluripotency and differentiation transcription factor , Oct4 . 
 
Oct4 is considered as a master transcription factor for pluripotent cell self-renewal. A 
defined Oct4 level controls the establishment of naive pluripotency as well as 
commitment to all embryonic lineages (Rapicavoli, Poth et al. 2010; Sheik Mohamed, 
Gaughwin et al. 2010; Radzisheuskaya, Chia Gle et al. 2013). Recent studies 
characterized mouse Gomfu/MIAT as a co-activator of Oct4 in a regulatory feedback 
loop. In this study we evaluate the relationships between human MIAT and Oct4 
expression. Towards this end, RNAi-mediated MIAT-silencing as well as shRNA Oct4 
knockdown will be performed in leukemic cell lines. Development of recombinant 
lentiviruses for delivery of shRNA guarantee the high and consistent suppression of 
targets. Affected cells will be analyzed for modulation in expression of MIAT and Oct4 
targets through real time analysis. Western blotting analysis following loss of function 
of either MIAT or Oct4 targets provide additional confirmation. Complementary study 
of correlation between MIAT and Oct4 will attain through gain of function studies. 
Thus, we will try to over-express MIAT by developing  an expression construction 
contains MIAT ORF. In conclusion, The expected results will be used to explain the 
molecular network in which MIAT regulated. It also might open a window to 
understanding the role of MIAT in differentiation of Leukemic cell. 
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CHAPTER 3. MATERIALS AND METHODS 
 
3.1. Plasmids 
 
pGIPZ lentiviral vector for Oct4 shRNA (GIPZ POU5F1 shRNA Transfection Starter 
Kit GE healthcare, dharmacon, USA, Cat# RHS4287-EG5460). 
This plasmid is designed to express short hairpin RNA (shRNA) constructs which 
designed based on microRNA-30 Hairpin. pGIPZ lentiviral vector adds a Drosha 
processing site to the hairpin construct and has been shown to greatly increase gene 
silencing efficiency(Boden, Pusch et al. 2004). The hairpin stem consists of 22 nucleotides 
of dsRNA and a 19 nucleotides loop from human miR-30. Adding the miR-30 loop and 
125 nucleotides of miR-30 flanking sequence on either side of the hairpin results in greater 
than 10-fold increase in Drosha and Dicer processing of the expressed hairpins when 
compared with conventional shRNA designs (Silva, Li et al. 2005). Increased Drosha and 
Dicer processing translates into greater shRNA production and greater potency for 
expressed hairpins. Use of the miR-30 design also allows the use of ‘rules-based’ designs 
for target sequence selection. One such rule is the destabilizing of the 5' end of the 
antisense strand, which results in strand specific incorporation of microRNA/siRNAs into 
RISC. pGIPZ lentiviral vector map shown in Figure 3.1. To assure the highest possibility 
of modulating the gene expression level, Oct4 gene is represented by four shRNA 
constructs, each covering a unique region of the target gene. Features of the vector 
depicted in Figure 3.2. 
The features that make this vector a versatile tool for RNAi studies include: 
• Ability to perform transfections or transductions using the replication incompetent 
lentivirus . 
• TurboGFP (Evrogen, Moscow, Russia) and shRNA are part of a bicistronic transcript 
allowing the visual marking of shRNA expressing cells. 
• Amenable to in vitro and in vivo applications. 
• Puromycin drug resistance marker for selecting stable cell lines. 
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Antibiotic resistance conveyed by pGIPZ include:  
Antibiotic concentratio
n 
Utility 
Ampicillin(carbencillin) 100μg/ml Bacterial selection marker (outside 
LTRs) 
Zeocin 25μg/ml Bacterial selection marker (inside 
LTRs) 
Puromycin variable Mammalian selection marker 
 
 
 
 
 
Figure 3.1: Map of pGIPZ Vector 
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Vector 
Element 
Utility 
hCMV Human cytomegalovirus promoter drives strong transgene expression 
tGFP TurboGFP reporter for visual tracking of transduction and expression 
Puro Puromycin resistance permits antibiotic selecting pressure and 
propagation of stable integrants 
IRES Internal ribosomal entry site allows expression of TurboGFP and 
Puromycin resistance genes in a single transcript 
ShRNA micrRNA-adapted shRNA(based on miR-30) for gene knockdown 
5ˊLTR 5ˊ long terminal repeat 
3ˊSINLTR 3ˊself-inactivating long terminal repeat for increased lentivirus safety 
Ψ Psi packaging sequence allows viral genome packaging using lentiviral 
packaging systems 
RRE Rev response element enhances titer by increasing packaging efficiency 
of full-length viral genomes 
WPRE Woodchuck hepatitis post transcriptional regulatory element enhances 
trans gene expression in target cells 
 
  
Figure 3.2: Feature of pGIPZ Vector 
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3.2. Primers and Probes 
 
The Primers and probes that used in this study are listed in Table 3.1. 
Table 3.1:   List of primers and probes 
Name Sequence Application 
MIAT 
Forward 
 
5' tactcgAGCTACAAAGACGACGCCGGCTG3' 
 
 (XhoI equipped) 
 
 
Cloning steps of   
MIAT 
MIAT Reverse  
5' agacGCGTGAATTGATTTTTAATAGCAAA3' 
 
 (MulI equipped) 
35MIAT 
Forward 
 
5' ctcgAGCTACAAAGACGACGCCGGCTGCGCTCGCG 3' 
 
Cloning steps of   
MIAT 
2126MIAT 
Forward 
 
5' ctcGAGGACAGCTCCAGGGGTATGAGGGAGGCCTG 3' 
6274MIAT 
Forward 
 
5' ctcGAGGCCTGTTGGTCTAGACTCTAGACTGTGGAG 3' 
 
Cloning steps of   
MIAT 
10148MIAT 
Reverse 
 
5' acGCGTGAATTGATTTTTAATAGCAAAATGGCATT 3' 
MIAT prob TaqMan® Gene Expression Assays  
 Cat no:4331182 
  
   
 
Real Time PCR 
OCT4 prob TaqMan® Gene Expression Assays POU5F1  
Cat no:4331182 
Human TBP 
(TATA-box 
binding 
Protein) 
Endogenous Control (FAM™/MGB probe, 
 non-primer limited),  Cat no:433376 
 
         CHAPTER3: MATERIAL AND METHODS 
 
Page54 
 
3.3. DNA and Protein Marker/Ladder  
 
• DNA Ladder(Gene Ruler)  
100 bp DNA Ladder,  (Invitrogen, Cat#15628-019) which  is suitable for sizing double-
stranded DNA from 100 to 1,500 bp.  
1 kb DNA Ladder(New England Biolabs,USA, Cat# N3232S) with effective size range 
between 500bp to 10,002bp.  
• Protein Marker 
Precision Plus Protein™ Kaleidoscope™ Standards #161-0375 which are a mixture of 
ten multicolor recombinant proteins (10–250 kD). 
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3.4. Cell lines and Cultures 
3.4.1. Cell lines 
 
The leukemic cell lines Were obtained from the American Type Culture Collection 
(ATCC, Manassas, VA,USA) or DSMZ (Deutsche Sammlung von Mikroorganismen und 
Zellkulturen, Germany) (Table 3.2). The human embryonic kidney cells HEK293FT 
transformed with the SV40 large T antigen were obtained from Invitrogen (Carlsbad, CA, 
USA).  
 
Table 3.2. leukemic cell lines. 
No Cell line Cell type Morphology Disease 
1 
GM1500 
lymphoblast B 
lymphocyte; Epstein-
Barr virus (EBV) 
transforme 
lymphoblast Lymphoma 
2 
B1 
Lymphoblastoid B 
cells 
Lymphoblastoid  CLL 
3 DB B lymphoblast lymphoblast large cell lymphoma 
4 
SU-DHL-6 
B lymphocyte lymphoblast-like large cell lymphoma; diffuse mixed 
histiocytic and lymphocytic 
lymphoma; follicular B cell lymphoma 
5 
ML1 
Myeloid leukemia 
lines 
Lymphoblastoid Human acute myeloblastic leukaemia 
6 
MOLM13 
acute myeloid 
leukemia 
most cells are round 
growing in suspension 
Acute myeloid  leukemia (Yuan, Loya 
et al.) 
7 
SEM 
B cell precursor  Round to polygonal 
single 
Acute lymphoblastic leukemia (ALL) 
8 CA-46 B lymphocyte lymphoblast Burkitt's lymphoma 
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9 
DOHH-2 
B cell lymphoma cells grow as single 
cells or in clumps in 
suspension 
immunoblastic B cell lymphoma 
progressed from follicular 
centroblastic/centrocytic lymphoma 
10 
MOLT4 
T cell leukemia round cells growing in 
suspension, singly or 
in clusters 
acute lymphoblastic leukemia (ALL) 
11 
NU-DHL-1 
 B lymphocyte early B-cell undifferentiated B lymphoma, non-
Burkitt's type 
12 SU-DHL-10 B Lymphocyte lymphoblast-like Large B Cell Lymphoma 
13 
SUPT11 
T-ALL  Small, polymorph cells T cell leukemia 
14 
Raji 
B lymphocyte Lymphoblast-like Burkitt lymphoma 
15 JURKAT T lymphocyte lymphoblast acute T cell leukemia 
16 Nalm-6   B cell precursor leukemia 
17 SU-DHL-8 B Lymphocyte lymphoblast-like Large B Cell Lymphoma 
18 
MV4;11 
macrophage lymphoblast biphenotypic B myelomonocytic 
leukemia 
19 
BL-41 
  Burkitt lymphoma 
20 
HL60 
  acute myeloid leukemia 
21 
WSU-DLCL-2 
B Lymphocyte Round to oval B cell lymphoma 
22 380 B Cell Precursor Round small cells B cell precursor leukemia 
23 BJAB   Burkitt lymphoma 
24 U937 Monocyte-like 
characteristics 
 Lymphoblast-like / 
Lymphocyte-like, 
round to polygonal, 
single cells 
histiocytic lymphoma 
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25 THP1 Monocyte Monocyte-like acute monocytic leukemia 
26 Namalwa   Burkitt lymphoma 
27 697 B cell leukemia rounded morphology B cell precursor leukemia 
28 MOLM14 acute myeloid 
leukemia 
most cells are round 
growing in suspension 
AML-M5a 
29 KARPAS-422 B cell Round to polygonal 
cells, growing singly 
or in small clusters 
Pleural effusion, B cell non-Hodgkin 
lymphoma (intra-abdominal, diffuse 
large cell lymphoma, refractory, 
terminal) 
30 CESS    
31 OCI-LY-19 B cell lymphoma single round cells 
growing in suspension 
Diffuse large B-cell lymphoma 
(DLBCL) 
32 RS4;11 B cell leukemia Lymphoblast-like / 
single, relatively small, 
round cells 
B cell precursor leukemia (ALL L2) 
33 KG1 Macrophage myeloblast acute myelogenous leukemia 
34 PER377 mature B-cell   ALL 
35 MEC1 Mature B cell round to polymorphic 
cells growing in 
suspension, singly or 
partly in small 
aggregates, a few cells 
are slightly adherent 
 chronic B cell leukemia  
36 MonoMac6   acute monocytic leukemia 
37 CCRF-SB   T cell leukemia 
38 DAUDI   Burkitt lymphoma 
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39 REH B cell  Lymphoblast-like / 
small, round, single 
cells 
Peripheral blood, Acute lymphoblastic 
leukemia, non-T; non-B, (ALL at first 
relapse) 
40 CI-1    
41 K562 NK cells lymphoblast chronic myelogenous leukemia (CML) 
42 NB4    acute promyelocytic leukemia (M3) 
 
3.4.2. Cell cultures 
 
All leukemic cell lines were cultured in RPMI 1640, 20% FBS and 1% Pen/strep. Medium 
for OCI-LY-19 cell line was MEM α, GlutaMAX™ Supplement, no nucleosides. 
HEK293FT were Cultured in Dulbecco's Modified Eagle's Medium(DMEM) 
supplemented with 10% fetal bovine serum (FBS), 100U/ml 0.1% (v/v) 
penicillin/streptomycin (Sigma, St Louis, MO). Specification of media used in this study 
listed in Table 3.3.  Cells were maintained in a humidified incubator at 37°C and 5% CO2 
and sub-cultured every 2-3 days .Early passages (passage 4–7) were used in each steps of 
the study. Freezing Media was prepared as 90%FBS+10% DMSO and was used while 
keeping on ice.  
 
Table 3.3. Cell culture media and reagents  
Medium Catalog Number Company 
Dulbecco's Modified Eagle's 
Medium 
D5796 Sigma Aldrich 
MEM-α glutamax no 
nucleosidase medium 
32561102   life technologies 
RPMI-1640 Medium R8758 R8758   Sigma Aldrich 
 
Penicillin-Streptomycin 
P4333 Sigma Aldrich 
Fetal Bovine Serum F2442 Sigma Aldrich 
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3.4.3. Counting the Cell Number 
 
At the indicated times, cells were trypsinized, (exclude suspended cells ) and the total 
number of cells per ml of media were counted using Scepter 2.0 Handheld Automated Cell 
Counter (Millipore Corporation, Billerica, MA, USA). 
 
3.5. Development of Lentivirus for shRNA Against Oct4 
 
3.5.1. Plasmid Preparation  
 
For plasmid preparation, all GIPZ shRNA clones were grown at 37 °C in 2x LB broth (low 
salt) medium plus 100 μg/mL carbenicillin only. Plasmid DNA was isolated using Endo 
Free Plasmid Maxi Kit cat# 12362, Qiagen as follows: 
1. Overnight LB culture was harvested by centrifuging at 6000 x g for 15 min at 4°C.  
2. The bacterial pellet was completely re-suspend in 10 ml Buffer P1.  
3. 10 ml Buffer P2 was added and mixed thoroughly by inverting 4–6 times, and incubated 
at room temperature (15–25°C) for 5 min. Because of using LyseBlue reagent, the  
solution turned blue. 
4. 10 ml chilled Buffer P3 was added, mixed thoroughly by inverting 4–6 times. The 
solution was mixed until it got completely colorless.  
5.Tube was centrifuged at max speed(4.7K at 4°C for 30 min) and supernatant recovered 
(27 to 30 ml) into 50 ml tube. 
6. 2.5 ml Buffer ER was added to the collected lysate, mixed by inverting the tube  
approximately 10 times, and incubated on  ice for 30 min.  
7. Equilibrated a QIAGEN-tip 500 by applying 10 ml Buffer QBT, and the column 
allowed  to empty by gravity flow.  
8. The lysate was applied from step 6 to the QIAGEN-tip and allowed to enter the tip.  
9. The QIAGEN-tip was washed with 2 x 30 ml Buffer QC. 
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10. DNA was eluted with 15 ml Buffer QN into a 50 ml endotoxin-free or pyrogen-free 
tube.  
11. DNA was precipitated by adding 10.5 ml (0.7 volumes) room-temperature isopropanol 
to the eluted DNA and mix. Centrifuged at 4300 x g for 60 min at 4°C. The supernatant 
carefully was decanted.  
12. DNA pellet was washed with 1 ml of endotoxin-free room-temperature 70%  ethanol 
and centrifuged at ≥15,000 x g for 10 min. The supernatant carefully was decanted without 
disturbing the pellet.  
13. In sterile condition the pellet was air-dried for 5–10 min and the DNA re-dissolved in a 
250µl volume of endotoxin-free sterilized water. 
 
3.5.2. Production and Packaging of Lentiviral Particles 
 
Trans-Lentiviral Packaging Kits (Thermo Scientific, Cat# TLP5912) was used to generate 
lentiviral particles. The production of lentiviral particles was begun with co-transfection of 
the Thermo Scientific Trans-Lentiviral packaging mix with an shRNA vector into 
HEK293T packaging cells, using the calcium phosphate reagent. Following co-
transfection, replication-incompetent virions are released into the medium for collection 
and downstream use.  
 
3.5.3. Cell Plating 
 
HEK293T cells seeded in a 6-well plate for each transfer vector to be packaged into   
lentiviral particles. 
1. The day before transfection, cells  was diluted in normal growth medium (DMEM 
High Glucose, Sodium Pyruvate, 10% FBS, 1% Pen/Strep) to achieve the optimal cell 
density of about 85-95% confluence at time of transfection. For each well of a 6-well 
plate, 1 × 10
6
 cells were prepared in 2mL medium. 
2. Cells was incubated at 37 °C with 5% CO2 overnight. 
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3.5.4. Co-Transfection with Calcium Phosphate Transfection Reagent 
  
The CaCl2 and 2x HBSS were thawed briefly in a 37 °C water bath. After thawing, both 
reagents may be stored for several weeks at 4 °C without detectable loss of function. 
Reagents should be brought to ambient temperature prior to proceeding with transfection. 
1. For each well of a 6-well plate, the indicated quantity of transfer vector DNA and 
Trans-Lentiviral Packaging Mix were prepared in a 5 mL (Fisher Scientific Cat #14-
959-1A) or 50 mL (Fisher Scientific Cat #14-432-23) polystyrene tube. Sterile water 
used to bring DNA mix to the indicated total volume. 
 
 Lentiviral Transfer 
Vector DNA 
(shRNA or ORF) 
Trans-Lentiviral 
Packaging Mix 
Total Volume 
(with sterile 
water) 
One well of a 6-
well plate 
6 µg 4.3 µL 135 µL 
 
2. The indicated volume of CaCl2 was added to the diluted DNA above: 
 Cacl2 
One well of a 6-well plate 15 
 
3. The tube was vortexed at a speed sufficient to thoroughly mix reagents without 
spillover. While vortexing, the indicated volume of 2x HBSS was added drop – wise: 
 2X HBSS 
One well of a 6-well plate 150 µL 
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4.Incubated at room temperature for 3 minutes. A light chalky precipitate was appeared 
during this incubation (the precipitate may not always be obvious). 
5. The total volume (300 µL) of transfection mix was added drop-wise to the cells.  
Note: The exact volume may be slightly less due to pipetting loss, but this will not 
negatively impact transfection efficiency.  
6. The cells were incubated at 37 °C with 5% CO2 for 10-16 hours (do not extend this 
time).  
7. After 16 hours of incubation, the cells were examined microscopically for the presence 
of a fluorescent reporter protein, TurboGFP as an indicator of transfection efficacy. 
Note: The color of the medium may be orange or orange/yellow; this does not affect viral 
production. 
8. Reduced serum medium was prepared as follows: 
a. High Glucose DMEM (Fisher Scientific Cat #SH30243.LS) 
b. 5% Fetal Bovine Serum (Fisher Scientific Cat #SH30070.03) 
c. 2 mM L-glutamine (Fisher Scientific Cat #SH30034.01) 
d. 1x Penicillin/Streptomycin (Fisher Scientific Cat #SV30010) 
9. Calcium phosphate-containing medium was removed from cells and replaced with the 
indicated volume of reduced serum medium: 
 Reduced serum medium 
One well of a 6-well plate 2ml 
 
10. The cells were incubated at 37 °C with 5% CO2 for an additional 48 hours. 
Note: Transfection efficacy can be determined by Fluorescent microscopy of GFP ,before 
harvesting 48 hours supernatant. 
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3.5.5. Viral Particle Collection and concentration 
 
1. Viral particle-containing supernatants was harvested 48 hours after the medium change 
by removing medium to a 15mL sterile, capped, conical tube and stored at 4
o
C. 
2. 2ml  reduced serum medium was added to each well again and the cells incubated at 
37°C with 5% CO2 for an additional 24 hours. 
3. Viral particle-containing supernatants harvested after 24 hours by removing medium to 
the last 15 mL sterile, capped, conical tube contains 48 hours supernatant.  
4. non-adherent cells were pelleted by centrifugation at 1600 × g at 4 °C for 10 minutes to 
pellet cell debris. 
5. After the low-speed centrifugation step, to remove any remaining cellular debris, 
filtration step was done in which supernatant was passed through a sterile 0.45 µM low 
protein binding filter ( Millipore Millex-HV 0.45 µM PVDF filters). 
6. Lenti-X™ Concentrator  (Clontech Cat. Nos. 631231 & 631232) was used for 
concentrating of virus particles.         
7. 1 volumes of clarified Viral supernatant from step 6 was mixed with 3 volume of the 
Lenti-X Concentrator and incubated overnight at 4°C.  
8. Sample was centrifuged at 1,500 x g for 45 minutes at 4°C. After centrifugation, an off-
white pellet will be visible. 
9. Supernatant was carefully removed. Residual supernatant was removed with either a 
pipette tip or by brief centrifugation at 1,500 x g. 
10. The pellet gently was re-suspend in 1/100th of the original volume using RPMI1640 
without serum and antibiotics. The pellet can be somewhat sticky at first, but will go into 
suspension quickly.(when add RPMI to the pellet, don’t shake or agitate it).  
11. The mixture was incubated at 4°C for overnight.  
12. The mixture was centrifuged at max speed ,4°C for 15 minutes. 
13. Supernatant was recovered and aliquoted into small volumes.  
14. single-use aliquots were immediately stored at –80°C. 
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3.5.6. Viral Iteration 
 
1. The day before transduction, a 24-well tissue culture plate was seeded with HEK293T 
Cells at 5 × 104 cells per well in DMEM (10% FBS, 1% pen-strep). 
Note: The following day, each well should be no more than 40-50% confluent. 
2. Dilutions of the viral stock were made in a round bottom 96-well plate using serum-free 
media(Figure 3.3 A). The goal was to produce a series of 5-fold dilutions to reach a final 
dilution of 390,625-fold. 
3. 80 μL of serum-free media was added to each well. 
4. 20 μL of thawed virus stock was added to each corresponding well in column 1 (five-
fold dilution). 
Note: Pipette contents of well up and down 10-15 times. Discard pipette tip. 
5. With new pipette tips, 20 μL from each well of column 1 was transferred to the 
corresponding well in column 2. 
Note: Pipette up and down 10-15 times and discard pipette tip. 
6. With new pipette tips, 20 μL from each well of column 2 was transferred to the 
corresponding well in column 3. 
Note: Pipette up and down 10-15 times and discard pipette tip. 
7. Repeated transfers of 20 μL from columns 3 through 8, pipetted up and down 10-15 
times and changing pipette tips between each dilution. 
8. the dilutions of the virus stock was incubated for 5 minutes at room temperature. 
9. The 24-well plate was labeled as shown in (Figure3.3 B) using one row for each virus 
stock to be tested. 
10. Culture media was removed from the cells in the 24-well plate. 
11. 225 μL of serum-free media was added to each well. 
12. Cells were transduced by adding 25 μL of diluted virus from the original 96-well plate 
(Figure 3.3 a.) to a well on the 24-well destination plate (Figure 3.3 B.) containing the 
cells.  
13. Transduced cultures were incubate at 37 °C for 4 hours. 
14. Remove transduction mix from cultures and add 1 mL of DMEM (10% FBS, 1% Pen-
Strep). 
15. Culture cells for 48 hours. 
16. Count the TurboGFP expressing cells or colonies of cells. 
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Note: Count each multi-cell colony as 1 transduced cell, as the cells will be dividing over 
the 48 hour cultureperiod.  
17. Transducing units per mL (TU/mL) can be determined using the following formula: # 
of TurboGFP positive colonies counted × dilution factor × 40 = # TU/mL. 
 
 
  
Figure 3.3. (A). Five-fold serial dilutions of virus stock (B). Twenty-four well tissue culture 
plate, seeded with HEK293T cells, used to titer the virus. 
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3.5.7. Transduction of Recombinant Lentiviral Particle  
 
The day before transduction, 1 × 105 HEK293T cells were seeded in a 12-well tissue 
culture plate in 1ml DMEM (10% FBS, 1% Pen/Strep). The following day, the wells 
should be no more than 40-50% confluent.  Transduction mix was prepared by adding 1μl 
Polybrene (Hexadimethrine bromide – Sigma #H9268) to desired amount of Viral particle 
and scaled up to 1ml with DMEM (without serum, 1% Pen/Strep). The media was 
aspirated and transduction mix was added gently onto the cells. plate was incubated for 4 
to 8 hours at 37
o
C. Transduction mix was removed from cultures and 1mL of DMEM 
(10% FBS, 1% Pen/Strep) added gently to each well. Cells kept in culture for 72 hours and 
GFP efficacy was monitored using fluorescent microscope. 
3.5.8. Infection of Target Cells  with Recombinant Lentiviral Particle  
 
1*10
5
 target cells was mixed with 0.5μl Polybrene (Hexadimethrine bromide – Sigma 
#H9268) and 500μl of RPMI in a capped cuture tube .Appropriate amount of recombinant 
viral particle or control virus was added to the mixture. Centrifuged in 2000g, Room 
Temperature (24
o
C) for 180 min. Then incubated overnight at 37
 o
C. After completing the 
incubation time, the mixture was centrifuged at 1000 rpm 10 min RT. The supernatant 
aspirated and the pellet was re-suspended in 0.5 ml RPMI with 10 % FBS and 1% 
antibiotics and seeded in 24 well for 48-72 hours. 
 
3.6. Cloning of MIAT ORF 
 
3.6.1. Restriction Enzyme Digestion 
 
A) Materials and Reagents  
• DNA sample in water or TE buffer 
• 10x digestion buffer 
• Restriction enzyme 
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B) Procedure 
1. The following reagents were pipetted into a microfuge tube: 
 
Material Final concentration 
Vector  0.1 to 4µg 
TE Buffer  (10X) 1X 
RE enzyme 1-5u/μg DNA 
ddH2O Rest of volume 
Final volume 30µl 
 
 
2. Incubated for 2 hours at 37◦C. 
3. 2 to 5 μl of the digested sample along with the uncut DNA and a DNA marker were 
run on agarose gel and checked for the exact size of resulted fragments. 
Tips: 
• For checking DNA, 0.1 μg DNA was used 
• For cloning, 4 μg DNA was used. 
 
3.6.2. Ligation 
 
Ligation was done with 50 ng of cut and purified vector in combination with 3-fold molar 
excess of insert in the presence of 1μl T4 ligase (Fermentase,USA) and 1μL of 10X T4 ligase 
buffer. Total volume was adjusted at 10μl with ddH2O. Ligation control was included with 
substituting the amount of insert with water. It allows evaluating the relegation efficiency. 
The ligation reactions were incubated at 15oC in a thermocycler for overnight. 
 
3.6.3. Competent Cells 
Transformation was done in DH5α-T1 bacterial competent cells. invitrogen cat# K4530-
20.  
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3.6.4. Transformation 
 
Transformation was done according to manual of One Shot® TOPO®TA Cloning® Kit for 
sequencing, invitrogen cat# K4530-20.  
A) Materials and Reagents  
• The TOPO® Cloning reaction from Set up the TOPO® Cloning reaction 
• LB plates containing 50 µg/mL ampicillin or 50 µg/mL kanamycin  
• 15-mL snap-cap plastic culture tubes (sterile) (electroporation only)  
• 42°C water bath  
• 37°C shaking and non-shaking incubator  
• General microbiological supplies (e.g., plates, spreaders)  
Components supplied with the kit:  
• S.O.C. medium   
Prepare for transformation  
• A water bath to 42°C  was equilibrated (for chemical transformation)  
• The vial of S.O.C. medium warmed to room temperature.  
• Selective plates warmed at 37°C for 30 minutes .  
• 1 vial of One Shot® cells for each transformation thawed on ice.  
 
B) One Shot® chemical transformation procedure 
1. 2 µL of the TOPO® Cloning reaction was added into a vial of One Shot® 
chemically competent E. coli and mix gently. Do not mix by pipetting up and down.  
2. Incubated on ice for 5–30 minutes. Note: Longer incubations on ice do not seem to   
affect transformation efficiency.  
3. The cells were heat-shocked for 30 seconds at 42°C without shaking.  
4. The tubes immediately transferred to ice.  
5. 250 µL of room temperature S.O.C. medium was added. 
6. The tube was capped tightly and shaked horizontally (200 rpm) at 37°C for 1 hour.  
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7. 10, 25, 50 and 100µL from each transformation (and 50 µL  from negative) were 
spreaded on a pre-warmed selective plate and incubated overnight at 37°C.  
3.6.5. Glycerol Stocks Preparation 
Every plasmid construct, whether it was created or purchased, maintained as a glycerol 
stock. 
A) Materials and Reagents 
• Appropriate LB media, liquid & solid.  
• 80% Glycerol (80ml autoclaved glycerol was mixed with 20ml autoclaved ddH2O). 
 
B) Procedure 
1. A single colony of the clone picked off of a plate and grown in the appropriate 
selectable liquid medium for overnight (e.g., LB with desired antibiotic).  
2. The construct was labelled (clone ID # and date). Placed this label onto a sterile 
screw cap of cryo-vial and then placed on ice. 
3. 0.5ml of the o/n culture was added to 0.5ml of 80% sterile glycerol in the sterile 
screw cap micro centrifuge tube (on ice) and vortexed. 
4. the glycerol stock was freezed at –80°C  
5. All pertinent information (host strain, vector, cloning site(s), selection criteria, date 
prepared, origin/source and/or reference, and any other important information) 
regarding this accession were entered into the lab stock collection book. Also 
include a map or sequence if possible.  
To streak out from a glycerol stock  
1. The location of the construct was determined. 
2. the tube was took and placed onto dry-iced box  
3. A portion from the top of the frozen glycerol stock scraped off using a plastic 
inoculating loop and streaked onto plate. 
         CHAPTER3: MATERIAL AND METHODS 
 
Page70 
 
3.6.6. Manipulation of DNA  
 
3.6.1.1. Plasmid Mini prep 
 
In cloning and sub-cloning steps of plasmid DNA, QIAGEN Plasmid Mini  kit 
(cat≠12125) (Qiagen, Hilden, Germany) was used according the manufacturer's instruction 
.  
3.6.1.2. Recovery of DNA fragments from the gel 
 
Recovery and of DNA fragments from the agarose gel was performed by dialysis method 
as follows:  
1. The gel was put into the dialysis membranes containing 0.5 ml buffer TBE 
2. Two sides of membrane were closed by clips  
3. The membrane was put in the electrophoresis tank contains 0.5 % TBE as  electrical 
flows go through negative to positive for 30 min at 100 V. 
4. Buffer included DNA was collected from bag(250µl) and transferred to a tube and 
DNA extracted as follows:  
3.6.1.3. Extraction of DNA by Phenol-Chloroform 
 
A) Materials and Reagents 
• phenol:chloroform:isoamyl alcohol (25:24:1) 
• chloroform isoamyl alchohol 
• TE buffer 
B) Procedure 
1. 200µl of phenol:chloroform:isoamyl alcohol (25:24:1) was added to the sample and 
vortexed or shakeed by hand thoroughly for approximately 20 seconds. 
2. Centrifuged at room temperature for 5 minutes at 16,000 × g. The upper aqueous 
phase was carefully aspirated and transferred to a fresh tube. Be sure not to carry 
over any phenol during pipetting. 100µl TE buffer was added to precipitate and 
mixed well. 
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3. Centrifuged at room temperature for 5 minutes at 16,000 × g. The upper aqueous 
phase was carefully aspirated and transferred to the previous separated aqueous 
phase. 
4. 300µl chloroform isoamyl alchohol was added to the tube and centrifuged at room 
temperature for 5 minutes at 16,000 × g. The upper aqueous phase was carefully 
aspirated and transferred to a fresh tube. 
5. Proceeded to Ethanol Precipitation. 
3.6.1.4. Ethanol Precipitation 
 
A) Material and Reagents 
Reagent Volume 
Glycogen (20 μg/μL) 1 μL 
7.5 M NH4OAc 25µl 
100% ethanol  
 
B) Procedure 
1. The reagents in the listed order in above table, were added to the aqueous phase of 
extraction procedure (see above). 
2. The tube was placed at –20°C overnight to precipitate the DNA from the sample. 
3. The sample was centrifuged at 4°C for 30 minutes at 16,000 × g to pellet the DNA. 
4. The supernatant was carefully removed without disturbing the DNA pellet. 
5. 500 μL of 70% ethanol was added and centrifuged at 4°C for 5 minutes at 16,000 × 
g. The supernatant was carefully removed. 
6. The pellet was dried at room temperature for 5–10 minutes. 
7. The pellet was resuspended in adequate volume of H2O . 
8. Centrifuged briefly to collect the sample, and was placed on ice. 
         CHAPTER3: MATERIAL AND METHODS 
 
Page72 
 
3.6.1.5.  Quantification of DNA 
  
The amount of DNA was measured by a Nanodrop® spectrophotometer (ND-
1000)(Thermo scientific). 
 
3.7. Quantitative Molecular Assays 
 
3.7.1. RNA Assay 
 
3.7.2.1. RNA Extraction 
 
 RNA of cell lines were extracted using TRIzol method. In the case of cells infected with 
lentivirus, we used RNA Clean Up and Concentration Kit (Norgen Cat# 23600 ) 
• RNA Extraction using TRIzol®  
 
A) Material and Reagents 
• TRIzol®Reagent(Ambion®) (Invitrogen, Cat#: 15596-018)  
• Chloroform ( Sigma Aldrich, Cat#: C2432-500ML) 
• Isopropanol  100% 
• Ethanol   75% 
 
B) Procedure 
Cultured cells were harvested, washed with PBS and pelleted by centrifuging at 200×g for 
5 min. The cell pellet was dissolved in 1mL of TRIzol®Reagent. The homogenized 
samples were incubated for 5 minutes at room temperature to permit complete dissociation 
of the nucleoprotein complex. 0.2 mL of chloroform per 1mL of TRIzol was added and the 
tubes were shaked vigorously by hand for 15 seconds. After 2–3 minutes incubation at 
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room temperature, the samples were centrifuged  at 12,000×g for 15 minutes at 4°C. The 
aqueous phase of the samples were aspirated and placed  into new tubes. 0.5mL of 100% 
isopropanol was added to the aqueous phase, for 1mL of TRIzol® Reagent used for 
homogenization. The samples were incubated  at room temperature for 10 minutes 
followed by centrifuge at 12,000×g for 10 minutes at 4°C. The RNA pellets were washed 
with 500μL of 75% ethanol. The samples were vortexes briefly, then centrifuged at 7500 × 
g for 5 minutes at 4°C. The wash was discarded. the RNA pellets were air dried for 5–10 
minutes and re-suspended  in 30μl of in RNase-free water. Absorbance of RNA at 260 nm 
and 280 nm was used to determine concentration. Extracted RNA were qualified on the 
0.8% agarose gel. 
• RNA clean up and concentration kit(Norgen Cat# 23600) 
The Protocol for RNA Clean-up and Concentration from Phenol/Guanidine Based RNA 
(Trizol or Tri Reagent) Isolation Methods was followed as below: 
1. Sample Preparation 
a. RNA was Isolated using a phenol/guanidine-based reagent such as Trizol or Tri Reagent, 
according to manufacturer’s instruction. After the separation of the aqueous and organic 
phases, the upper (aqueous) fraction containing the RNA was collected into a new RNase-
free microcentrifuge tube . Note the volume. 
b. Added one volume of 70% ethanol (provided by the user) to the fraction from step 1a. 
Mixed by vortexing for 10 seconds. 
2. Binding to Column 
a. Assembled a column with one of the provided collection tubes.  
b. Applied up to 600 µL of the RNA mixed with the ethanol (from Step 1b) onto the 
column and centrifuged for 1 minute at ≥ 3,500 x g (~6,000 RPM). 
Note: Ensure the entire sample volume has passed through into the collection tube by 
inspecting the column. If the entire lysate volume has not passed, spin for an additional 
minute at 14,000 x g (~14,000 RPM). 
c. Discarded the flow through. Reassembled the spin column with its collection tube. 
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d. If the volume of RNA mix is greater than 600 µL, repeat Steps 2b and 2c until all the 
remaining RNA mix has passed through the column. 
3. Column Wash 
a. Applied 400 µL of Wash Solution A to the column and centrifuged for 1 minute. 
Note: Ensure the entire Wash Solution A has passed through into the collection tube by 
inspecting the column. If the entire wash volume has not passed, spin for an additional 
minute.  
c. Discarded the flow through and reassemble the spin column with its collection tube. 
d. Repeated steps 3a and 3b to wash the column a second time. 
e. Washed column a third time by adding another 400 µL of Wash Solution A and 
centrifuging for 1 minute.  
f. Discarded the flow through and reassembled the spin column with its collection tube. 
g. Spined the column for 2 minutes in order to thoroughly dry the resin. Discarded the 
collection tube. 
4. RNA Elution 
a. Placed the column into a fresh 1.7 mL Elution tube provided with the kit.  
b. Added 20 µL of water to the column.  
Note: For higher concentrations of RNA, a lower elution volume may be used. A minimum 
volume of 20 µL is recommended. 
c. Centrifuged for 2 minutes at 200 x g (~2,000 RPM), followed by 1 minute at 14,000 x g 
(~14,000 RPM) Note the volume eluted from the column. If the entire volume has not been 
eluted, spin the column at 14,000 x g (~14,000 RPM) for 1 additional minute.  
 Note: For maximum RNA recovery, it is recommended that a second elution be  
performed into a separate micro centrifuge tube (Repeat Steps 4b and 4c).  
5. Storage of RNA 
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The purified RNA sample may be stored at –20°C for a few days. It is recommended that 
samples be placed at –70°C for long term storage. 
3.7.2.2. Quantification of the extracted RNA 
 
Quantified the RNA in Nanodrop and measured absorbance at 260 nm and 280 nm. 
(A260/280 of >1.8 was considered for assessment of quality of RNA. Partially dissolved 
RNA samples have an A260/280 ratio <1.6).  
 
3.7.2.3. DNaseI treatment of extracted RNA  
 
A) Materials and Reagents 
DNase I, Amplification Grade, manufactured by life technology, Unite size,100U 
Catalog #s 18068−015, Lot No. 1465877 
B) Procedure 
The following materials were added to an RNase-free, 0.5-ml microcentrifuge tube on ice: 
1 µg RNA sample 
1 µl 10X DNase I Reaction Buffer 
1 µl DNase I, Amp Grade, 1 U/µl 
DEPC-treated water to 10 µl 
Tube was incubated for 15 min at room temperature. The DNase I was inactivated by the 
addition of 1 µl of 25mM EDTA solution to the reaction mixture. Heated for 10 min at 
65°C. 
NOTE: It is important not to exceed the 15-minute incubation time or the room 
temperature incubation. Higher temperatures and longer time could lead to Mg++-
dependent hydrolysis of the RNA. Additionally, it is vital that the EDTA be added to at 
least 2mM prior to heat-inactivation to avoid this problem. 
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3.7.2.4. cDNA synthesis  
 
A) Materials and Reagents 
Super Script VILO DNA synthesis Kit (Invitrogen™ Cat #s 11754-050) 
B) Procedure 
For a single reaction, the following components were combined in a tube on ice. For 
multiple reactions, a master mix was prepared without RNA.  
 
 
component concentration 
5X VILO™ Reaction 
Mix 
1X 
10X SuperScript® 
Enzyme Mix 
1X 
RNA 100ng 
DEPC-treated water -- 
Total volume 10μl 
 
 
2. Tube contents was gently mix and incubated at 25°C for 10 minutes.  
3. Tube was incubated at 42°C for 120 minutes.  
4. The reaction was terminated at 85°C at 5 minutes.  
5. Stored at –20°C until use.  
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3.7.2.5. Real Time PCR 
 
A) Materials and Reagents 
1. Human TBP (TATA-box binding Protein) Endogenous Control (FAM™/MGB probe, 
non-primer limited), Life Technologies, Cat# 433376 
2. TaqMan Gene Expression Assays , Life Technologies, Cat# Hs00402814_m1  
3. TaqMan® Gene Expression Assays POU5F1, Life Technologies, Cat no:4331182 
4. Optical 96-Well Fast Thermal Cycling Plate with Barcode (code 128), part No. 
4346906. 
5. Fast advantage 2X real time master mix 
B) Protocol 
Components Final concentration 
2X TaqMan Universal Fast PCR Master Mix 1X 
20X Taq Man Gene Expression Assay for 
MIAT,TBP,OCT4 
1X 
cDNA Sample 1:4 diluted 
RNase-free Water Up to 20μl  
Each sample was loaded in triplicate. PCR was done in Biorad-Chromo4 thermal cycler 
real 
time PCR instrument as follows: 
Sample Volume: 20 No. of Cycles:  40 
Step UNG incubation Ampli Taq Gold Active. PCR 40 Cycle 
Action Hold Hold Denature Anneal/Extend 
Temperature 50 oC 95 oC 95o C 60o C 
Fast chemistry 
time 
2 min 20 min 1 min 20 min 
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3.7.2.6. polyA SpinTM mRNA Isolation kit( New England Biolabs, 
Cat#S1560S)  
 
polyA SpinTM mRNA Isolation was used for isolation of mRNA from other RNA (like 
rRNA, tRNA and snRNA) in a RNA samples. Isolation procedure was done according to 
the manual of instructor as follows:  
 • Allow oligo (dT)25-cellulose, column(s) and buffers to come to room temperature. 
• Prepare a 65–70°C bath and an ice bath.  
• Spin tube containing oligo (dT)25-cellulose in a micro centrifuge for 10 seconds. Using a 
micropipette remove storage buffer. Be careful  to avoid drawing of cellulose beads into 
pipette tip. 
• Equilibrate cellulose by adding 200 µl of Wash Buffer to cellulose beads, mix thoroughly 
then micro centrifuge for 10 seconds. Using a micropipette decant supernant.  
• Pre warm Elution Buffer in 70°C bath. 
Isolation Procedure 
1.100µl of Cl1 nuclear RNA(891 ng/µl) and 60µl of Cl1 cytoplasmic RNA( 485 ng/µl) 
were diluted with Elution Buffer to final volume of 450 µl. 
2 . Add 50 µl of 5M NaCl per 450 µl total RNA solution.  
3 . Heat at 65°C for 5 minutes and quickly cool in an ice bath for 3 minutes. 
4 . Apply total RNA solution to equilibrated oligo (dT)25 -cellulose, seal cap and mix 
thoroughly . Let stand at room temperature for 5 minutes agitating by hand or place 
horizontally on rotary shaker 5 . Micro centrifuge for 10 seconds .  Note: It is important to 
agitate beads during binding, washing and elution steps . 
6 . Pipet supernatant back into original micro centrifuge tube . Repeat steps 3 thru  . 
7 . Pipet supernatant back into original micro centrifuge tube for storage . It is 
recommended that no spin-column elutes be discarded until entire isolation procedure is 
completed and the results are evaluated . Elutes can be stored in sterile test tubes on ice . 
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8 . Add 400 µl of Wash Buffer to oligo (dT)25 -cellulose beads . Agitate by hand to 
resuspend the cellulose beads . Using a 1 ml micropipette with sterile pipette tip, transfer 
Wash Buffer and beads to the column reservoir of a clean micro centrifuge spin column 
unit (provided with kit) . 
9 . Let stand at room temperature for 2 minutes agitating by hand or place horizontally on 
rotary shaker . Micro centrifuge for 10 seconds . Remove column reservoir and transfer 
column eluent to a clean 13 x 100 mm test tube . 
10 . Add 400 µl of Wash Buffer to column reservoir and wash as in Step 9 three times . 
11 . Using the same method wash column once with 400 µl of Low Salt Buffer . 
 *Note: This wash step with 0 .1 M NaCl removes residual poly(A)– RNA which is bound 
to the cellulose column . This step can be omitted during a second round purification . 
12 . Remove spin-column reservoir and place in a clean micro centrifuge tube (provided 
with kit) .  
13 . Add 200 µl of pre warmed Elution Buffer to column reservoir . Agitate by hand 
resuspending the cellulose beads . Let stand for 2 minutes agitating by hand or place on 
rotary shaker . Micro centrifuge for 10 seconds .( we add 50 and 100µl in two independent 
rounds) 
14 . Repeat Step 12 using fresh pre warmed Elution Buffer. (we add 50µl in two 
independent rounds only for nuclear sample) 
15 . Place Elution Buffer eluate on ice. 
 
3.7.2. Protein Assay 
 
3.7.2.7. Protein Isolation 
  
Total protein from mammalian cell lines were prepared using RIPA lysis buffer (150mM 
NaCl, 0.1% SDS, 0.5% sodium deoxycholate, 1% NP-40) (Sigma, St Louis, MO) with 
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complete protease and phosphatase inhibitor cocktails (Sigma, St Louis, MO,USA). 
Homogenates were then centrifuged at 13000 rpm for 15 min at 4°C and supernatants 
collected. Protein concentration was measured using Bradford Reagent and the BSA 
Protein for tracing a standard curve. 
3.7.2.8. Western Blotting 
 
A) Reagents and Solutions 
• SDS-PAGE Running Buffer 
Tris-base 3.0 g 
Glycine 14.4 g 
20% SDS 5 ml 
Add ddH2O to 1 L 
• Western Blot Transfer Buffer 
Tris-base 3.0 g 
Glycine 14.4 g 
Methanol 200 ml 
Add ddH2O to 1 L 
• TBS Buffer(pH 7.4) 
Tris-base 2.420 g 
NaCl 8.78 g 
Add ddH2O to 1 L 
Adjust the pH to 7.4 
• TBST Buffer  
0.05 % tween 20  
Add to TBS Buffer 
• Western Blot Blocking Buffer 
5% milk 
Add to TBS Buffer 
Mix well and filter 
• Ponceau Red Staining Solution 
Ponceau S 0.5g 
Acetic acid 25 ml 
Add ddH2O to 500 ml 
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B) Procedure 
Thirty micrograms of total extracted protein were loaded onto 4-15% Mini-
PROTEAN® TGX™ Precast Gels (Bio-Rad Laboratories,Hercules,CA94547). The 
separated proteins were transferred to PVDF membranes (BioRad) for 2h at 100mA. After 
blocking with 5% non-fat milk ,the membrane was incubated with Oct4 primary antibody 
(Anti- OCT4 antibody adcam cat# 19857) (concentration: 1µl/ ml), dilution 1:1000). 
GAPDH (mouse) (concentration dilution 1:15000) was used for normalization purposes at 
4
◦
C overnight. The membrane was washed three times in TBST buffer, each for 10min. 
Then followed by incubation  with Anti-Mouse IgG (whole molecule)–Peroxidase 
antibody produced in rabbit (Sigma Aldrich,A9044 dilution 1:10000) to recognize the 
primary antibodies for 1hr. at room temperature. Signals were developed with Precision 
Plus Protein Dual Color Standard (BIO-RAD) and Protein bands were visualized using the 
ChemiDoc
TM
MP Imaging System and quantified using Image lab 4.0 software (Bio-Rad 
Laboratories,Hercules,CA94547). 
 
3.8.  Quantitative Cell Analysis 
3.8.1. CellTiter-Glo® Luminescent Cell Viability Assay  
 
The CellTiter-Glo® Luminescent Cell Viability Assay is a homogeneous method to 
determine the number of viable cells in culture based on quantitation of the ATP present, 
which signals the presence of metabolically active cells. 20000 Leukemic Cells transferred 
to 96-white-walled microtiter plates. Cell viability was determined by adding 100μl of the 
CellTiter-Glo luminescent cell viability kit (catalog# G7571) from Promega Corporation 
(Madison, WI, USA) directly to cells suspended in serum-supplemented mediumand The 
plate was incubated for 90min at room temperature in a dark room to stabilize luminescent 
signal. For each sample, triplicate wells were considered. Also we considered wells 
without cells as a blank control as negative background controls. The contents were mixed 
for 2 minutes on an orbital shaker to induce cell lysis. Luminescence was recorded in 
Infinite F200 PRO multimode microplate reader(Tecan Group Ltd, Seestrasse 1038708 
Männedorf ,Switzerland). Calculation of results was done by subtracting the average of 
luminescence value of the culture medium background from all  Luminescence value of 
experimental wells. Data were confirmed in at least two independent experiments. 
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3.8.2. Caspase-Glo® 3/7 Apoptosis Assay 
 
The Caspase-Glo® 3/7 Assay is a luminescent assay that measures caspase-3 and -7 
activities in purified enzyme preparations or cultures of adherent or suspension cells. The 
assay provides a proluminescent caspase-3/7 substrate, which contains the tetrapeptide 
sequence DEVD. This substrate is cleaved to release aminoluciferin, a substrate of 
luciferase used in the production of light. The Caspase-Glo® 3/7 Reagent is optimized for 
caspase activity, luciferase activity and cell lysis. Addition of the single Caspase-Glo® 3/7 
Reagent in an "add-mix-measure" format results in cell lysis, followed by caspase cleavage 
of the substrate and generation of a “glow-type” luminescent signal. For preparation of the 
reagent the Caspase-Glo® 3/7 Buffer and lyophilized Caspase-Glo® 3/7 Substrate were 
equilibrated to room temperature before use. Then the contents of the Caspase-Glo® 3/7 
Buffer bottle was transferred into the amber bottle containing Caspase-Glo® 3/7 Substrate. 
The contents was mixed by swirling or inverting, until the substrate is thoroughly dissolved 
to form the Caspase-Glo® 3/7 Reagent.  
Caspase-3/7 activity was measured immediately after the detection of CellTiter-Blue® Cell 
Viability Assay (described above) on the same wells, by adding 100µl of the homogeneous 
Caspase-Glo® 3/7 assay Reagent (catalog#G8091)(Promega Corporation ,Madison, WI , 
USA) at the established time after transfection, to each well of a 96-well plate containing 
100µl of blank or negative control cells. Because of the sensitivity of this assay, the plate 
was covered with a plate lid. contents of wells gently was mixed using a plate shaker at 
300–500rpm for  30 seconds, depending upon the cell culture system. The optimal 
incubation period was determined empirically between 60, 90 and 120min. the 
luminescence of each sample was measured in a plate-reading illuminometer (infinite F200 
PRO) (Tecan Group Ltd, Seestrasse 1038708 Männedorf ,Switzerland), as directed by the 
luminometer manufacturer. The value for the blank reaction which show the background 
luminescence from experimental values was subtracted. Negative control reactions were 
important for determining the basal caspase activity of the cell culture system and vehicles. 
Caspase-3/7 activity is expressed as luminescence of treated sample / mock control×100. 
Data were confirmed in at least two independent experiments. 
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3.8.3. MTS assay 
 
The CellTiter 96® AQueous One Solution Cell Proliferation Assay(a) is a colorimetric 
method for determining the number of viable cells in proliferation or cytotoxicity assays. 
The CellTiter 96® AQueous One Solution Reagent contains a novel tetrazolium compound 
[3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-
tetrazoliu m, inner salt; MTS(a)] and an electron coupling reagent (phenazine ethosulfate; 
PES). PES has enhanced chemical stability. The experiment was established by adding 
20µl of CellTiter 96® AQueous One Solution Reagent into each well of the 96-well assay 
plate containing the samples in 100µl of culture medium. We used multichannel pipettes 
for convenient delivery of uniform volumes of CellTiter 96® AQueous One Solution 
Reagent to the 96-well plate. The plate was incubated at 37°C for 15 min in a humidified, 
5% CO2 atmosphere while covering to avoid light 96-well plate reader. Absorbance was 
measured at 490nm using a plate-reading illuminometer (infinite F200 PRO) (Tecan Group 
Ltd, Seestrasse 1038708 Männedorf ,Switzerland), as directed by the luminometer 
manufacturer.   
3.9. Statistical Analysis 
 
Significance was determined by the two-tailed Student’s test. A p-value threshold < 0.05 
was considered significant. All real time PCR (assayed in triplicate), Western blotting, and 
transfection experiments were repeated twice, and reproducible results were obtained. 
Values were presented as the mean ± standard deviation (Carninci, Kasukawa et al.). 
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CHAPTER 4. RESULTS 
4.1.  LncRNA MIAT is Differentially Expressed Among 
Leukemic Cell Lines 
 
A total of 42 leukemic cell lines were analyzed for MIAT expression including 7 ALL,  2 
CLL, 10 AML, one CML, 19 B cell lymphoma and 4 T cell leukemia cell lines. 
The 7 ALL cell lines included 380,697, RS4;11, SEM, Nalma6 with the characteristic of  B 
precursor leukemic cells, PER377 which originated from mature B cell and REH which 
derived from the peripheral blood of a non B, non T acute lymphoblastic leukemia (ALL at 
first relapse) patient.  
In the group of CLL , MECI derived from the peripheral blood of a patient with B-chronic 
lymphocytic leukemia (B-CLL) in prolymphocytoid transformation to B-PLL. B1 cell 
characteristics established from a chronic lymphocytic leukemia clone by in vitro EBV 
infection. 
The 10 AML cell lines included NB4, HL-60 as promyeloblast leukemic cell type, 
Monomac6, U937,THP-1, MOLM13, MOLM14 that derived from peripheral blood of a 
patient with acute monocytic leukemia, CESS with lymphoblast cell type from 
myelomonocytic leukemia and KG1, MV4;11 with cell type of macrophage and ML-1 
which originated from lymphoblast. 
The only CML cell line, K562, derived from a CML patient in blast crisis. Analysis of 
properties of B and T lymphocytes showed that K562 is not a B cell line, while it has some 
T cell properties. 
The 19 B cell lymphoma included BJAB,BL41,Raji,Daudi,CA46,Nalmava, CI-1 belong to 
Burkitt lymphoma, DoHH2,SU-DHL-6 from follicular B cell lymphoma, NU-DHL1 early 
B cell from non-differentiated B lymphoma, GM1500, WSU-DLCL-2 with lymphoblast 
morphology and DB, SU-DHL-8, SU-DHL-10, OCI-LY-19,Karapas form large B cell 
lymphoma.  
The Four T Leukemia cell lines included CCRF-SB, SUP11, MOLT4 and JURKAT.  
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Total RNAs of cell lines were extracted and treated by DNase I, Amplification Grade Kit in 
order to eliminate genomic DNA contamination. 80 ng of purified total RNAs was used in 
cDNA synthesis reaction using Super Script VILO DNA synthesis Kit (Invitrogen™ Cat 
#s 11754-050) (see material and methods for details). Real Time PCR was done providing 
TaqMan Gene Expression Assays probe for MIAT (Life Technologies, Cat# 
Hs00402814_m1), in three replicates for each samples. Human TBP (TATA-box binding 
Protein)( FAM™/MGB probe, non-primer limited (Life Technologies, Cat# 433376)) was 
selected as endogenous Control. The results were depicted in Figure 4.1. The lowest level 
of MIAT was detected in ALL and AML as well as CML cell lines. MECI cell line 
belonging to CLL type, showed moderate level of MIAT.  In B cell lymphoma variable 
expression of MIAT from low to high was detected. B lymphoma cell lines with Low 
expressed MIAT mostly had Lymophoblast-like morphology. Two cell lines, SU-DHL-6 
and DOHH2 originated from follicular B cell lymphoma fell down in category of moderate 
MIAT expression. Other member of B lymphoma cell lines with moderate level of MIAT  
expression originated from Burkitt lymphoma or Large B cell lymphoma. In the group of 
high MIAT expression which included CI1,DB and Nalmava, the highest level belonged to 
CI1 cell lines. CI1 cells are at intermediate stages of B-cell differentiation with 
abnormalities involving chromosomes 2, 8 and 22 and its karyotype was 46, XX, t(2;8) 
t(14;22). The t(2;8) had the same breakpoints as those reported in some cases of Burkitt's 
lymphoma. DB cell line which established from ascites of a 45-year-old caucasian man 
with diffuse large cell lymphoma; assigned to GCB-like lymphoma subtype (germinal 
center B-cell) was stand for the second high MIAT expression B Lymphoma. Nalmava  
belonged to Burkitt lymphoma ,too. It also did not seem a correlation between MIAT 
expression and differentiation stage of B cells. T cell leukemia cell lines showed also a 
variable level of MIAT expression from low to moderate.  
In conclusion, CLL and B cell lymophoma cell lines express significant high level of 
MIAT whereas AML,ALL and CML cell lines did not show a considerable MIAT 
expression. T cell leukemia cell lines are variable in MIAT expression (Figure 4.2.). 
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Figure 4.1: MIAT expression in Leukemic cell lines. Differential expression of MIAT in leukemic cell lines was examined through Real time PCR using specific taqman probe for MIAT and 
normalized according to TBP (TATA binding protein) expression. Data are represented as mean values +/- SD from three replicates. Percentage of of 2
-Δct
 was used to explain the MIAT 
expression. 
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Figure 4.2: MIAT expression in different type of Leukemia cell lines. Data are 
represented as mean values +/- SM from each group.   
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4.2. CLL Patients Differentially Express MIAT Transcript  
 
80 CLL patient’s RNA were subjected for survey of MIAT expression. The study was 
approved by the Ethics Committee of the Ohio State University of Medical Center (OSUMC), 
and written informed consent was obtained from all patients and subjects. The expression 
level of MIIAT was evaluated by Real Time PCR. The experiment was done in triplicates for 
each samples. The percentage of 2
-Δct 
of MIAT target gene and TBP as normalizer gene was 
used to compare the differential expression of MIAT in representative CLL patients (Figure 
4.3A). CLL patient’s samples were classified according to four main cytogenetic changes to 
11q del, 12 trisomy, 13q del and 17p del. As depicted in Figure 4.3B. Evaluation of mean of 
MIAT expression in each group revealed that mean of  MIAT expression in group of 17p del 
is significantly higher than Del(13q) by 61% (p value 0.001). Predicting features of CLL 
patients with 17p del showed more aggressiveness, poor prognosis and outcome and these 
patients tend to have higher-risk disease. As well CLL patient with cytogenetic abnormality of 
17p del usually do not respond to standard initial therapy whereas CLL patients with 13q del 
with no other chromosomal abnormalities are associated with a relatively more favorable 
outcome(1). MIAT expression in 11q del and 12 trisomy, were relatively high comparing to 
13q del by 37% (p value: 0.014) and 57% (p value: 0.002) respectively. The proportion of 
CLL patients with del 11q tend to be younger with large lymph nodes and have high-risk 
disease. Regarding to these information, Suggested that there should be a relation between 
MIAT expression in CLL patients and prognosis features of the disease.
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Figure 4.3. MIAT expression in CLL patient. A: relative expression of MIAT in four of cytogentic different group 
of CLL patients.B: mean of lncRNA MIAT expression in each cytogenetic groups of CLL patients. Results were 
shown as mean+/- SD . Expression of MIAT were significantly higher in 11q del (p value 0.014), 12 trisomy (p value 
0.002) and 17pdel (p value: 0.001) respect to 13q del. 
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4.3.  Transcription Factor Oct4 Modulates MIAT Expression  
 
For an in-depth understanding the molecular pathway of MIAT function the expression of 
transcription factor Oct4  was studied which is suggested as regulator of long non coding 
RNA of Gomafu in mouse Esc(2). Providing cDNAs which synthesized in step 3.1 and 3.2, 
expression level of Oct4 were analyzed in CLL patients as well as Leukemic cell lines by 
using specific probe for human Oct4 (TaqMan® Gene Expression Assays POU5F1, Life 
Technologies, Cat no:4331182) in a real time PCR reaction. TBP (Life Technologies, Cat# 
433376) was used as reference gene. The mean expression of MIAT and Oct4 in each four 
cytogenetic types of CLL was compared. Interestingly we found that the expression of 
Oct4 was highest in 17p del group and gradually decreased in 12 trisomy and 11q del 
toward 13q del (Figure 4.4 A). This results was in accordance with expression of MIAT in 
different cytogenetic groups of CLL samples that  were analyzed in this study, suggesting a 
possible transcriptional regulation of MIAT by Oct4. Analyzing the Oct4 expression in 
leukemic cell lines revealed the same results, as in CLL and B lymphoma were detected 
the highest expression of Oct4 as well as MIAT(Figure 4.4 B). Next, western blot analysis 
was used to compare protein levels of Oct4 in leukemic cell lines.  leukemic cell lines 
CI1,MEC1 and DB with high expression of MIAT  and  leukemic cell lines NU-DHL-1, 
BJAB and BL-41 with low expression of MIAT were cultured and proceed to protein 
extraction as described in material and method (Figure 4.5.). We observed higher 
expression of Oct4  protein level in CI1 and DB cells that also had been shown higher 
expression of  MIAT transcribed during Real time PCR (Step 3.1). The lowest Oct4 protein 
was observed in BL-41 and NU-DHL-1 with very low expression of MIAT expression. 
While BJAB with low expression of MIAT transcript still showed moderate Oct4 
expression in protein level. These results validated that Oct4 and MIAT transcript could 
participate in a feedback regulation. 
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          Figure 4.4: Quantities real time PCR for Oct4 transcript and MIAT. Result were 
established through as mean values +/- SD from three replicate (p value<0.05). A:  Oct4 
transcript expression in CLL patients. Oct4 as well as MIAT express highly in 17pdel 
CLL samples. The least expression of Oct4 was achieved in 13q del CLL patients that was in 
accordance with MIAT expression. B: Oct4 expression in Leukemic cell lines. The mean of 
Oct4 expression in each category of leukemic cell lines represent the same pattern of lncRNA 
MIAT expression.   
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Figure 4.5. Western Blot analysis of POU5F1(Oct4) protein in leukemic cells. CI1 , MECI and 
DB which express lncRNA MIAT at highest level showed higher expression of Oct4 at protein level. 
NUDHI1 did not show any expression of Oct4 protein. Oct4 expression in BL41 was low. BJAB cell 
line showed medium level of Oct4 protein. The latest three cell lines distinguished as low expressing 
MIAT leukemic cell lines. GAPDH was employed as reference normalize 
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4.4. Knockdown of lncRNA MIAT in leukemic cell lines 
 
4.4.1. Figuring out the most Effective Leukemic Cell Line for Chemical 
Transfection of Synthetic Oligos like siRNAs 
 
As the transfection in suspend cell lines like leukemic cell lines is not feasible as adherent cell 
lines, Leukemic cell lines that showed high expression of MIAT were selected as DB, CI1 and 
MEC1 to be checked for transfection efficacy with different chemical reagents for 
transfection. Transfection of BLOCK-iT™ Fluorescent Oligo(invitrogen) using lipofectamine 
2000(invitrogen) and Dharmafect (GE) and reverse transfection using Neo FX Rt 
reagent(invitrogen) were compared in DB,CI1,MEC1. 4.5*10
4 
DB, CI1 and  MEC1 cells were 
seeded into 96 well plates on the day of transfection for transient transfection. HEK-293 cell 
line which known as easily transfect among adherent cell lines, transfected with BLOCK-iT™ 
Fluorescent Oligo in parallel, to compare the efficiency of different chemical transfection 
reagents and stability of BLOCK-iT oligo during times (Data not shown). For HEK-293,  
0,8*10
4
 cells were seeded into 96 well plate on the day before transfection for transient 
transfection, however for reverse transfection using Neo FX Rt reagent (invitrogen), 2.5*10
4
  
cells  were used on the day of transfection. The cells were monitored during 5 days using 
florescent microscope. After 24,48,72,96 and 120 hours post-transfection, transfection 
efficiency was determined under florescent microscope. Among leukemic cell lines, DB and 
CI1 were detected as the best transfectable cell lines in comparison with MEC1 (Figure 4.6.). 
On the base of transfection efficacy, DB and CI1 cell lines were selected for the next steps. 
Also we checked three different concentrations of BLOCK-iT™ Fluorescent 
Oligo(invitrogen) (10nM,50nM, and100nM), and different volume (0.2μl,0.5μl and 1μl) of 
lipofection reagents of Lipofectamine 2000(invitrogen) and Dharmafect (GE) in DB and CI1 
cell lines. Our goal was set up the best effective transfection situation with the least 
cytotoxicity. According to Figure 4.7 the results showed the best transfection efficacy with 
100nM concentration of  BLOCK-iT™ Fluorescent Oligo trasfected using 1μl of  Dharmafect 
(GE) reagent. 
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Figure 4.6. Transfection effiency of leukemic cell lines. DB, CI1 and MEC1transfected with BLOCK-iT 
florescent oligos to compare  the efficiency of transfection. Features of transfected cells after 48 hours 
visualized under light microscope(10X) . DB and CI1 were detected as most efficient during lipofection 
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Figure 4.7. Set up analysis for lipofection of synthetic oligos.  10μM ,50μM and 100μM Block-iT oligos 
were transfected with different concentration as well as reagents available for lipofection. Efficiency of 
transfection was revealed 48h after transfection under florescent microscope (10x). 100μM oligo trasfected 
using 1μl of Dharmafect reagent showed to be the most efficient . 
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4.4.2. MIAT Knockdown in CI1 and DB Cell Lines 
 
100nM of Human MIAT siRNA was transfected in DB and CI1 cell lines (5*10
5
 DB and CI1 
cells in 24 well plates) using Dharmafect (GE) Transfection reagent. We used a pool of 4 
siRNAs reaction to achieve the most effective knockdown of MIAT. In this experiment 
Negative controls was established for verification of experiment. Negative control cells were 
transfected by ON-TARGETplus Non-targeting siRNA in the same concentration and 
condition of target siRNA. Cell lines harvested in different time points 24h,48h,72 and 96 
hours and subjected for analysis of MIAT expression level through Real Time PCR. The 
experiment was done in biological triplicates. Technical replicate for Real Time PCR reaction 
was also considered. The results are shown in Figure 4.8 for DB and CI1 cell lines. According 
to the real time PCR results single transfection of 100nM siRNA against MIAT was able to 
inhibit the expression of MIAT by 26% (p value: 0.01) in DB cells and 14% (p value: 0.04) in 
CI1 cells, for 24 hours. However at longer time their effect diminished, suggesting degradation 
of synthetic siRNA by RISC complex. To reach the most efficient knockdown of MIAT, we 
increased the amount of siMIAT and transfected it in DB for 24 hours. ON-TARGETplus 
Non-targeting siRNA as negative controls were considered for verification of experiment. This 
result showed that the best rate of knocking down of MIAT was seen in 150nM of siRNA 
against MIAT respect to negative control. The value of down regulation was achieved by 
32.7% (p value=0.01) in time point 24 hours (Figure 4.9). 
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Figure 4.8.Directected know down of MIAT in DB and CI1 cells. DB and CI1 cell lines were 
transfected with 100nM MIAT siRNA and negative oligo as control. Real Time PCR of transfected 
cells for 24,48,72 and 96 hours showed that MIAT down regulation was achieved for 24h post 
transfection. The value of down regulation was higher in DB by26% respect to 14% in CI1(P 
value<0.05). 
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4.4.3. Directed Knockdown of the lncRNA MIAT Promotes Down 
Degulation of Oct4  
 
To check whether the lncRNA MIAT might participate in a feedback loop affecting the level 
of Oct4 transcription factor, we examined if RNAi against MIAT could change Oct4 mRNA 
levels in leukemic cell lines. siRNA transfection was done in DB leukemic cell lines. 5*10
5
 
DB cells were seeded into 24 well plates on the day of transfection. Transfection was done 
using 100nM of Human MIAT siRNA and transferred to the cell by Dharmafect (GE) 
Transfection reagent. The same concentration of ON-TARGETplus Non-targeting siRNA #1 
Figure 4.9. Different concentration of siRNA for know down of MIAT in DB cells. DB 
cell line was transfected with 75nM, 100nM and 150nM of MIAT siRNA and negative oligo 
as control. Real Time PCR of transfected cells after 24 hours post transfection revealed using 
150nM of siRNA, we can  down regulate MIAT expression by 32.70% (P value=0.013).  
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were transfected in negative control cells. Cells  harvested after 24 hours and level of lncRNA 
MIAT and mRNA of Oct4 were analyzed through Real Time PCR providing specific probes 
for MIAT and Oct4 and TBP as normalizer. The results showed that siRNA of MIAT resulted 
in reduced mRNA level of Oct4 (Figure 4.10.). Interestingly, increasing concentration of 
RNAi against MIAT, affected the RNA level of Oct4 as well as MIAT down regulation 
(Figure 4.10.). That means transcription of MIAT and Oct4 are regulated in a potential 
synergistic feedback mechanism.  
 
 
 
Figure 4.10. RNAi mediated know down of MIAT, down regulate the expression of Oct4. DB cell line 
was transfected with 75nM, 100nM and 150nM of MIAT siRNA and negative oligo as control. Real Time 
PCR was done for Oct4 and MIAt as well. 12.9% and 9.6% down regulation of Oct4 expression were 
observed using 100nM and 150nM of siRNA against MIAT respectively. Knockdown efficiency of MIAT 
was validated by showing  32.7% and 22.07% reduction of MIAT expression level in samples transfected by 
100nM and 150nM of siRNA against MIAT respectively. *P value<0.01, **P value<0.05.  
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4.4.4. Directed Knockdown of the lncRNA MIAT Decreased cell 
Proliferation and Induced Apoptosis in Leukemic Cell Lines 
 
To check whether lncRNA MIAT transcript level reduction is correlated with alteration in  
cell viability and programmed cell death levels, three sequential rounds of transfection of  
Human MIAT siRNA in DB cell lines was employed. We proposed that continuous 
transfection ensure the highest and continuous inhibition over the 72-hour time course ,that 
is needed for cell function studies. 5*105 DB cells were seeded into 24 well plates on the 
day of transfection and 150nM of Human MIAT siRNA was transfected by Dharmafect 
(GE) Transfection reagent. In this experiment, Negative scrambled oligo was used as 
control (ON-TARGETplus Non-targeting siRNA # Dharmacon). Three sequential rounds 
of transfection of Human MIAT siRNA (GE company) were done at 0, 24h and 48h. To be 
sure that repeating transfection by lipofection reagent has no considerable toxic effect,  the 
viability of cells were analyzed by MTS Assay during the time points (Data not shown).  
Before each rounds of transfection, cells washed gently with complete media and seeded in 
wells again. After 72 hours cells harvested and proceed to RNA extraction step by 
NORGEN RNA Clean Up and Concentration Kit. Real Time PCR reaction was done in 
significant statistical replicates for each samples. The results showed that triple transfection 
of siMIAT, significantly depleted endogenous level of MIAT by 51% relative to 
nonsilencing control siRNA-transfected (p value=0.001), confirming that these lncRNAs 
are susceptible to Dicer-mediated suppression (Figure 4.11A). Furthermore, we showed the 
co-downregulation of MIAT and Oct4 RNA level is still detected (Figure 4.11A), which 
powering the hypothesis of existence of a potential synergistic feedback mechanism 
between lncRNA MIAT and transcription factor, Oct4. 
Also we showed that lncRNA MIAT RNAi induced apoptosis by 40%(P value0.007) 
corresponding to negative control treated cells(Figure 4.11BI) after 96 hours from starting 
point of experiment. Consistently the number of viable cells decreased by 10% (P value 
0.05) (Figure 4.11 BI). The lesser effects was observed in 72 time point (Figure 4.11 BII). 
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Figure 4.11. Cell based assay mediated knockdown of MIAT by siRNA. A: Down regulation of MIAT 
as well as Oct4 were detected following triple transfection of DB cells with siRNA against MIAT. B: 
Apoptosis and cell proliferation assay following directed knockdown of MIAT by siRNA. BI . After 96 
hours from the start point of experiment, 40% (P value 0.007) induction in apoptosis and 10%(P value 0.05) 
decrease in viability were observed.  BII. Apoptosis and viability of cells transfected with siRNA through 
three days did not show any significant chang related to the control.  Control was considered as not 
transfected DB cells 
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4.5. Oct4 Knockdown by shRNA Mediated Lentiviral delivery: 
in vitro Study 
 
4.5.1. Development of Recombinant Lentivirus for shRNA against Oct4  
 
ShRNA against Oct4 were delivered as 4 individual constructs of : V3LHS-311240, 
V3LHS-311241, V3LHS-311243 and V2LHS-222507. A set of four expression constructs 
were used to guarantee that at least one of the four, offered an efficient knockdown for 
Oct4 with 50% or more. Lentivius for shRNA clone collection against Oct4 as well as 
control viral particles were produced in HEK-293T Cells, providing Thermo Scientific 
Trans-Lentiviral shRNA Packaging Kit including helper plasmids which co-transfected 
with expression constructs using  Calcium Phosphate Transfection Reagent (see details in 
material and methods). Transfection efficacy of four individual constructs were monitored 
48h post-transfection for GFP reporter under fluorescent microscopy (Figure 4.12.). 
Transient transduction of four recombinant lentiviral particles were done in HEK293 cells 
to determine the most efficient viral particle for transduction of target cells. For each 
individual viral particle, transduction efficiency of 1*10
5
,2*10
5
 and 4*10
5
 IU were 
compared. The efficacy of transduction monitored under fluorescent microscopy, 72 hours 
post transduction. The results showed  that the most efficient  transduction of recombinant 
lentiviral particle achieved using 4*10
5
 IU compare to IU 2*10
5
 and 1*10
5 
(Figure 4.13.A). 
Infected cells with recombinant lentiviral particle at IU 4*10
5
 were trypsinized and 
harvested 72 hours post infection and proceed to protein extraction. Western blot analysis 
of Oct4 was done by using Oct4 antibody (Anti- OCT4 antibody adcam cat# 19857) 
(concentration: 1µl/ ml), dilution 1:1000). GAPDH (mouse) (concentration dilution 
1:15000) was used for normalization ( Figure 4.13.B).  The results showed that lentivirus 
V3LHS-311241 knockdown Oct4 effectively compared to other viral particles. 
 
 
         CHAPTER4: RESULTS 
 
 
Page103 
 
 
 
 
 
 
 
 
 
 
Figure 4.12. Transfection efficiency of four Oct4 shRNA expression constructs. Untransfected 
sample considered as a negative control for GFP expression. 
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Figure 4.13. A.Transduction efficiency of four Oct4 shRNA lentivirus. DB cells were infected with recombinant  
Lentivirus at 1*10
5
,2*10
5
 and 4*10
5
 IU. Infection efficiency and concentration of  each particle were compared by 
florescent features of GFP reporter expression. B. Western blot analysis for Oct4. Functionality of four recombinant 
particles for Oct4 knockdown was determined at protein level, 72h after infection. Mouse GAPDH was used for 
normalization. The most efficient viral paricle was determined as LentiV3LHS-311241. 
A 
B 
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4.5.2. Lentiviral Delivery of shRNA Suppress the Expression of Oct4 in 
Leukemic cell line 
 
The ability of shRNA mediated lentiviral delivery to knock-down endogenous Oct4 was 
assessed in DB cells. toward this end, Virus no V3LHS_311241 was selected  for 
transduction because of its higher efficacy in transduction of HEK293 cells (see section 
3.5.1.). pGIPZ non-silencing shRNA lentiviral control virus  RHS 4346 was used as 
Negative control in our experiment. 100000 cells were mixed with 0.5ml RPMI and 0.5 µl 
of Polybrene in one tube for each well of 24 well plate. Recombinant virus was added to 
the mentioned mixture with different IU 1*10
5
, 2*10
5
, 4*10
5
 and 10*10
5
. Centrifuged in 
2000g, Room Temperature for 180 min followed by Incubation over night at 37. The day 
after, Centrifuged at 1000 rpm 10 min RT. Aspirated supernatant and resuspended  pellet 
in 0.5 ml RPMI with 10 % FBS and 1% antibiotics and seeded  in 24 well plate. 
Cytotoxicity of recombinant virus was assessed by using MTS viability method which did 
not show any considerable cytotoxicity effect.  After 48  hours GFP expression studied in 
florescent microscope and DB cell line with more than 4*10
5
 IU of virus was selected for 
proceeding the experiment (data not shown). 
10*10
5
  DB cell lines were infected by 5*10
6
 virus expressing shRNA of Oct4 and control 
virus as well. Experiment was done in triplicate in 12 well plate . Figure 4.14A shows the 
efficacy of transduction which is monitored by GFP expression under fluorescent 
microscopy. Infected cells peletted 72 hours post infection and followed for RNA and 
protein extractions. The significant reduction of Oct4 mRNA by shRNA  resulted in Real 
Time PCR (-18,64 ± 5,634 difference between means shRNA oct4 v. control, P value= 
0.02 relative to control virus infected cells, N = 3 replicates). Lentivirus delivery of shRNA 
against Oct4 also significantly reduced protein level of Oct4 (P < 0.001 relative to control 
virus infected cells). These data demonstrated that shRNA against Oct4 provides an 
effective knockdown.  
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Figure 4.14. shRNA-Oct4 knockdown mediated lentivirus delivery. A. Fluorescent features of 10*10
5
  DB 
cell lines which infected by 5*10
6
 virus(10X) represent the percentage of infected cells.  B. Real time PCR 
analysis for Oct4 mRNA. shRNA directed Oct4 knockdown resulted in around 18,64 ± 5,634 fold reduction of 
Oct4 mRNA, compared with the control virus infected samples, 3 d post-infection (p value <0.01). C. Western 
blot analysis of POU5F1/Oct4 protein, confirmed an robust downregulation of protein level of Oct4 in 
comparison with control virus in DB cells. GAPDH protein was employed as reference normalize. 
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4.5.3. Oct-4 knockdown Modulates MIAT Expression 
 
To further explore whether MIAT modulation following Oct4 knockdown was concordant 
with Oct4 mRNA silencing using RNAi MIAT (see section 3.4.3.),  we examined whether 
shRNA against Oct4 mediated lentiviral delivery could change lncRNA MIAT transcript 
level in leukemic cells. Indeed, shRNA against Oct4 (Fig. 4.15) resulted in reduced levels 
of MIAT as shown by real time PCR(P <0.01). In conjunction with RNAi MIAT-mediated 
suppression of Oct4, the result suggests the potential for an auto feedback loop between 
lncRNA MIAT and Oct4. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
Figure 4.15.  Differential expression of lncRNA MIAT upon robust Oct4 shRNA knockdown. 
shRNA-directed Oct4 knockdown resulted in down-regulation of MIAT compared with the non 
target control virus infected, 3 d post-infection. (Asterisks) Significant difference from control 
samples(*, P < 0.05; **, P < 0.01).  
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4.5.4. Induced Apoptosis and Depleted Cell Viability Following Oct4 
Knockdown 
 
To establish whether Oct-4 knockdown induced changes in biological properties of 
leukemic cell lines, DB cells were infected with lentivirus express shRNA against Oct4( 
IU=10*10
5
). Cell apoptosis and viability were analyzed after 24,48,72 and 96 hours post 
infection. 20000 infected cells in each time points were used for caspase3/7 apoptosis as 
well as cell viability. At 24h time point the effect of Oct4 shRNA was not enough to show 
significant difference in apoptosis and viability, means that knockdown of the target OCT4 
transcripts was also time dependent. However after 48h, Oct4 knockdown leads significant 
specific effects on number of viable cells and cells went to programmed death(Figure 
4.16A).  Higher effect also observed at 72 h after infection (Figure 4.16A). Real Time PCR 
was done on harvested cells at 72 h to show that the existence differences in apoptosis and 
viability are consequences of Oct4 knockdown(Figure4.16B).   
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Figure 4.16.  Apoptosis induction and proliferation inhibition following Oct4 knockdown. A. Apoptosis 
and viability of DB cells infected with shRNA against Oct4 mediated lentivirus at IU 10*10
5
  significantly 
changes regards to control virus infected cells. Greater induction in apoptosis and inhibition of proliferation 
observed after 72 h post infection. B. Increase in apoptosis and Decrease in viability was a consequence of 
Oct4 as confirmed by real time PCR.   
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4.6. Development of Vectors for Over-expression of lncRNA 
MIAT  
 
We next asked whether over-expression of lncRNA MIAT coding sequence could 
modulate tumorogenesity-associated transcript levels. Moreover,  over-expression of 
MIAT introduce a new possibility for breakthrough in understanding the correlation 
between MIAT and Oct4 expressions.  In this step leukemic cell lines which express MIAT 
at high level were used as a source of MIAT template.  
4.6.1. LncRNA  MIAT is Enriched in the Nucleus  
There is growing evidence that lncRNAs are recruited to chromatin and epigenetically 
regulate gene expression(4). Thus, lncRNAs expected preferentially localized in the 
chromatin and nuclear RNA fractions, in contrast to protein-coding mRNAs that are 
trafficked to the cytoplasm for translation(5). There are also evidences that show spliced 
mature Gomafu RNA is localized to the nucleus despite its mRNA-like characteristics(6). 
We checked the localization of MIAT transcript in leukemic cell lines in which express 
high level of MIAT as DB, CI1 and MECI.  The cultured cells were dissolved in hypotonic 
solution and homogenized in homogenizer tubes. Centrifuging of homogenized solution 
separated the cytoplasmic and Nuclear compartments. Both cytoplasmic and nuclear 
fractions were followed for extraction of RNA using Trizol and Trizol LS (Invitrogen) 
reagents, respectively(see material and methods for details). 40ng of extracted RNAs were 
reverse transcripted to cDNA by  Super Script VILO DNA synthesis Kit (Invitrogen™ Cat 
#s 11754-050). Synthesized cDNAs were amplified in Real time PCR procedure using 
TaqMan specific probes for MIAT (Life Technologies, Cat# Hs00402814_m1) and TBP 
(Life Technologies, Cat# 433376) as reference control. Analysis of the Real time PCR data 
for nucleus and cytoplasm from three different B cell lines indicates that indeed the MIAT 
transcript is abundant in the nucleus over the cytoplasm. In Figure 7.17 we displayed the 
mean of percentage of 2
-Δct 
for three technical replicates of each samples. In all cell lines 
we observed a robust and highly statistically significant enrichment of lncRNAs in the 
nucleus (p value<0.05).  Highest differential ratio was belonged to DB by 50.7% MIAT 
enrichment in nuclear over cytoplasmic compartment(p value= 1,24E-05). 
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4.6.2. Cloning of MIAT ORF  
 
4.6.2.1. Isolation of polyA+ RNA from RNA Component  of Nucleolus 
 
LncRNAs possess mRNA-like features, as they generally undergo splicing, are transcribed 
by RNA polymerase II, and are polyadenylated. Most RNA component  of nucleolus  
included ploy(A)- RNAs like ribosomal RNA (rRNA), transfer RNA (tRNA) and 
small nuclear RNA (snRNA). Thus, we employed polyA Spin™ mRNA Isolation Kit  to 
isolate poly(A)+ RNA, like  lncRNA MIAT from total RNA of nuclear component. 
Poly(A)+ RNA selection kit (New England Biolabs,  Cat#S1560S) functions through 
affinity chromatography using pre-packed oligo (dT)25-cellulose beads.  PolyA Spin™ 
mRNA Isolation Kit was used according to manufacturer’s instruction. Because of their 
poly(A) tails and other mRNA-like features, lncRNAs are represented in typical cDNA 
cloning. We utilized poly(A) tails of lncRNA MIAT to made cDNA.  cDNA Synthesis was 
done by providing 0.5 µg/µl oligo(dT) 12–18 as well as random Primers in the 
SuperScript™ First-Strand cDNA synthesizing protocol.  PolyA+ RNA content of both 
Figure4.17. LncRNAs MIAT are enriched in the cell nucleus. the chromatin/cytoplasm expression ratios of lncRNAs 
in MECI, DB and CI1 cell lines. Data are represented as percentage of 2-Δct ratios of MIAT and TBP expression.  
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nuclear and cytoplasmic compartment were applied as template for reverse transcription. 
Then, the products of cDNA synthesis step were subjected for real time PCR using specific 
probes for MIAT (Life Technologies, Cat# Hs00402814_m1)  and TBP (Life 
Technologies, Cat# 433376) as a reference gene. As expected the load of MIAT in 
cytoplasmic compartment was lower than nucleus. Either Oligo(dT) or Random primers in 
PCR reaction did not effect on the amount of final product of polymerase reaction.  
 
4.6.2.2. Amplification of MIAT ORF 
We designed Forward primers from start point of MIAT transcript (NCBI Reference 
Sequence: NR_003491.2) and equipped it to XhoI restriction site and reverse primers from 
a few nucleotide upstream of polyA tail and equipped it to MluI restriction site. cDNA 
synthesized with oligo(dT) primer in step3.6.2.1. was used as template in a PCR reaction. 
As the size of our amplicon(MIAT) estimated to be between 9 to 10kb,  polymerization 
was done providing high fidelity, advantage HD polymerase(2.5U/µl) (clontech , cat# 
639241). PCR was done in three-Step as 98°C for 10 sec, 55°C for 5 sec and 72°C for 
10min(1 min/kb) for 30 cycles. At the end 1μl of Taq polymerase and dATPs was added 
and incubation was continued by a single extension at 72°C for 20min to add 3ˊA 
overhang to amplicons, which will facilitate cloning steps of PCR products in commonly 
use TOPO®TA Cloning vectors. Amplification of a 10kb PCR product was illustrated on 
agarose gel 0.8% in TBE 0.5x along with 1kb DNA ladder( Figure 4.18A). The 10kb and 
heavier bands were cut from the gel and kept in separate tubes (Figure 4.18B). Gel pieces 
transferred into the dialysis membrane containing 0.5 ml buffer TBE and the two sides of 
membrane closed thoroughly by clips.  The membrane lay down in the electrophoresis tank 
contains TBE 0.5x as  electrical flows go through negative to positive for 45 min 100 V 
Tank. the Buffer included DNA collected from bag and transferred to a tube.  
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Figure4.18.  PCR Amplification of MIAT ORF with around 10kb length, using MIAT forward and reverse primers 
digned in this study. Ploy A+RNA reverse transcript to cDNA using oligodt primers and subjected for amplification as a 
template. A. Eletophoresis of PCR product revealed a 10kb band. B. 10kb amplicon was cut from the gel for further 
cloning steps. 
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4.6.2.3. Engineering the clones, contain MIAT ORF 
DNA from previous step ,proceeded to Ethanol Precipitation (see material and methods for 
details). Cloning steps was done into TOPO®TA Cloning vector. The Ligated  products 
were then transformed into DH10β cells and allowed to grow overnight on ampicillin 
plates to select for cells containing plasmids. Screening of appropriate recombinant clones 
were done by PCR and restriction digestion analysis. Colony PCR screening was performed 
with primers flanked full sequence of MIAT transcript. polymerization was done providing 
high fidelity, advantage HD polymerase(2.5U/µl) (clontech , cat# 639241) in three-Step as 
98°C for 10 sec, 55°C for 5 sec and 72°C for 10min(1 min/kb) for 30 cycles. The PCR 
product visualized on the agarose gel 0.8% after electrophoresis at 80v for 45 min. As 
Figure 4.19A show, it seemed three over four clone contains our interest fragment. 
Restriction digestion screening of all four clones was done using EcoRI (New England) 
according to it’s manual. Two of four clones confirmed as correct clone after illustrating 
the digested PCR on gel agarose 0.8% along with 1kb DNA marker( Figure 4.19B). 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
Figure 4.19. Screening of recombinant construct contains MIAT. A. PCR screening, clone 1, 3 and 4 
contain our interest fragment with the size of 10kb. B. Restriction digestion screening. Red circle show the 
expected yielding fragments after cut with EcoRI. M: 1kb DNA marker. 
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CHAPTER 5. DISCUSSION 
 
Leukemia is cancer of the body's blood-forming tissues, including the bone marrow and 
the lymphatic system. The disease develops when blood cells produced in the bone 
marrow,  grow out of control. Approximately every 3 minutes one person in the United 
States (US) is diagnosed with a blood cancer. 71% of men survive leukemia (all subtypes 
combined) for at least one year, and this is predicted to fall to 54% surviving for five years 
or more. Survival for women is slightly lower, with 66% surviving for one year or more 
and 58% predicted to survive for at least five years. Traditionally biologists have 
concentrated their efforts on understanding the functions of coding genes. It may therefore 
be a little surprising that only a tiny fraction of the human genome encodes proteins, yet in 
contrast recent studies showed that the majority of our genome is transcribed into non-
coding RNAs (ncRNAs). NcRNAs include highly abundant and functionally important 
RNAs, such as ribosomal RNAs (rRNAs), transfer (tRNAs), small nuclear RNAs 
(snRNAs), and small nucleolar RNAs (snoRNAs). However, two classes of recently 
discovered ncRNAs, microRNAs (miRNAs) and long ncRNAs (lncRNAs), appear to play 
a significant role in the regulation of gene expression programs that occur in higher 
eukaryotes. LncRNAs, which are abundantly encoded in mammalian genomes, numbering 
in the tens of thousands, in contrast to microRNA-encoding genes, which are an order of 
magnitude less numerous. However, functionalizing the rich repertoire of long non-
protein-coding transcripts remains a challenge. LncRNAs may also be involved in all 
levels of gene expression regulation within the cell and, eventually, they have also been 
implicated in many diseases, including cancers. EGO was one of the first lncRNA to be 
identified in the hematopoietic system [63]. This lncRNA was identified in eosinophil 
differentiation of CD34+ HSCs where it stimulated differentiation and mature cell function 
by transcriptionally regulating eosinophil granule protein expression [62]. However, its 
mode of action has not yet been described. 
Nowadays, Long non-coding RNAs (lncRNAs) are increasingly recognized as important 
regulators of gene expression, chromatin structure and nuclear architecture. Although 
many thousand lncRNAs have been identified over the last years, little is known about 
their biological relevance in normal and cancerous development. 
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LncRNA MIAT/AK028326 has been previously described as retinal noncoding RNA 2 
(RNCR2), strongly expressed in the developing retina(Blackshaw, Harpavat et al. 2004). 
Subsequent studies have demonstrated that RNCR2/AK028326 is a 3′ terminal fragment of 
a ∽9-kb lncRNA, Gomafu/Miat, widely expressed in central nervous system 
neurons(Sone, Hayashi et al. 2007).  
Another study showed that RNCR2/AK028326 is also expressed in mESCs and may be 
regulated by ES-associated transcription factors. (Sheik Mohamed, J., P. M. Gaughwin, et 
al. (2010). Their original annotations described AK028326 as the nearest target to the Oct4 
ChIP-PET-supported binding site in the region; in addition, during the early stages of their 
work, EST evidence was lacking to conclusively link AK028326 to the Gomafu/Miat 
transcriptional unit (Sone et al. 2007). Both AK028326 and the Gomafu/Miat cDNAs were 
derived from a 5 cap-trapped, dT-primed cDNA library, suggesting that multiple 
transcriptional initiation and termination events, generating a variety of mature transcripts, 
including possibly the original AK028326 isoform, may take place at this locus. 
Although their results explore the synergy of Oct4 and AK028326 expression, they portray 
an apparently contradictory increase in mRNA levels of several differentiation markers 
when AK028326 is over expressed. While this particular finding may be due to over 
expression far beyond maximum endogenous levels that saturates the regulatory 
network and leads to unanticipated cell differentiation triggers, their results also do not 
exclude functional outcomes associated with the longer transcripts from this locus, whose 
expression did not investigate. 
Of potential relevance to their AK028326 work is the finding that MIAT, an lncRNA 
encoded at the human chromosome 22 locus orthologous to AK028326/Gomafu, is 
genetically associated with heart disease (Ishii et al. 2006) and, similarly to 
AK028326/Gomafu, exhibits multiple alternative transcription initiation and termination 
sites, which are supported by cDNA evidence and are accompanied in EST data by 
different expression specificities of the different transcripts encoded at the locus. It is 
therefore remarkable that RNAi and over expression of even a partial fragment of this 
particular lncRNA are sufficient to promote mESC differentiation under self-renewing 
conditions, and to promote meso- and ectodermal gene transcription, respectively. 
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The mechanisms by which AK028326 exert its impact, remain unknown but worthy of 
future studies. 
Our study provides the first evidence that MIAT/AK028326 is also expressed during 
hematopoetic malignancy, and may be regulated by ES-associated transcription factors 
(Oct4), expanding our understanding of this particular lncRNA by implicating it in 
regulatory networks outside of the central nervous system. 
In our quantitative analysis of the expression patterns of MIAT transcript in leukemic cell 
lines, the highest expression were shown to belong to B cell lymphoma. AML and ALL 
cell lines revealed the lowest level of MIAT expression.  
Gomafu is evolutionarily conserved from mammals to birds and amphibians (Rapicavoli et 
al. 2010; Tsuiji et al. 2011). The previous studies revealed that In contrast to NEAT1 and 
MALAT1, which are expressed in a wide range of tissues, Gomafu is only expressed in 
subsets of neurons (Blackshaw et al. 2004; Rapicavoli et al. 2010; Tsuiji et al. 2011). But 
in this study we showed that MIAT is expressed in lymphoma cell lines as well. 
We also associated the aberrant expression of MIAT with clinical significance by 
analyzing 80 Chronic lymphocytic leukemia (CLL) patient samples from four different 
cytogenetic abnormalities. CLL is the most prevalent type of leukemia which is  
characterized by a extremely variable clinical course: while some patients present quick 
progressive evolutions, others have an indolent course with more than 30 years of survival. 
51.7% of the CLL patients present chromosome abnormalities. The most important 
numerical and structural abnormalities found in CLL include trisomy 12 and deletions in 
several chromosome regions, such as 13q14, 11q, and 17p13, as well as other less 
frequently occurring aberrations. The most frequent observed aberration is del 13q14 
observed in 34.5% of cases and It is associated to other alterations in 17.2%. 17p13 
deletions are found in 17.2% and trisomy 12 in 13.8% (in isolation in 6.9% and associated 
to del 13q14, in 6.9% of the cases). An 11q22 deletion was found in one case associated to 
a 13q14 deletion.  
Nascimento et al evaluated the relationship between chromosome aberrations and other 
prognostic factors in CLL. They considered two cytogenetics groups: in isolation and no 
alteration) and unfavorable outcomes (trisomy 12, 17p13 deletion, 11q22 deletion and two 
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simultaneous alterations).The unfavorable alterations were more frequently seen among 
young individuals (<60y). 
We identified abundant expression of MIAT in unfavorable outcomes (trisomy 12, 17p13 
deletion, 11q22 deletion) compared to favorable (13q deletion) cytogenetic group. By this 
mean, MIAT expression might be associated to aggressiveness and poor outcome in CLL 
which also empower a proposed role for lncRNA MIAT in development and regulation of 
leukemiasis. Expanding this experiments may also issue MIAT to identify patient 
populations at risk of development of cancer and may classify patients into aggressive or 
mild cancer groups. 
Thus, analysis of the function of lncRNAs is expected to have a tremendous impact on the 
management of human disease, we also performed functional studies. Recently, the role of 
lncRNAs in pluripotency was examined in another study by interpreting the genomic 
context of the ncRNAs relative to nearby protein-coding genes and expression upon 
embryoid body (EB) differentiation. Out of the 945 ncRNAs expressed during EB 
differentiation, 174 were differentially expressed, many correlating with pluripotency and 
cell fate decisions (Dinger et al. 2008b). AK028326 (synonyms: Gomafu, MIAT) was 
among the 174 differentially expressed lncRNAs, but it was not singled out for in-depth 
regulatory or functional analysis in that study.  
In CLL patient samples and Leukemic cell lines, we showed the strong correlation between 
MIAT transcript and mRNA of Oct4. The mean expression of MIAT and Oct4 in each four 
cytogenetic types of CLL was compared. Interestingly we found that the expression of 
Oct4 was highest in 17p del group and gradually decreased in 12 trisomy and 11q del 
toward 13q del. This results was in accordance with expression of MIAT in different 
cytogenetic groups of CLL samples that  were analyzed in this study, suggesting a possible 
transcriptional regulation of MIAT by Oct4. Analysis of protein was somehow in 
accordance with quantitative transcript expression. We observed higher expression of Oct4  
protein level in CI1 and DB cells that also had been shown higher expression of  MIAT 
transcribed during Real time PCR . The lowest Oct4 protein was observed in BL-41 and 
NU-DHL-1 with very low expression of MIAT expression. These results validated that 
Oct4 and MIAT transcript could participate in a feedback regulation. 
Given the recent evidence that lncRNAs such as NRON, Evf-2, and MEG3 may directly 
co-regulate transcription factors, testing for direct interactions between Oct4 and 
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AK028326/Gomafu in the nucleus is a promising potential avenue for future investigation, 
especially given that nuclear localization of several other functional lncRNAs, including a 
regulatory lncRNA that forms a ribonucleoprotein complex with transcription factors in 
vivo (Bond et al. 2009), has been highlighted in recent studies (Hutchinson et al. 2007; 
Clemson et al. 2009). In view of these precedents, testing for interactions of the lncRNA 
Gomafu (MIAT) with the Oct4 protein may be promising and can be accomplished by gain 
and loss of function studies. 
We used RNAi to knockdown MIAT transcript in leukemic cell lines and showed that 
mRNA of Oct4 affected by this treatment to be significantly downregulated. Providing the 
timely Oct4 knockdown by developing lentiviruses express shRNA against Oct4 we 
validated regulation of MIAT and Oct4 in a potential synergistic feedback mechanism.  
The relevance to our  work is the finding that characterized mouse Gomafu/MIAT should 
be  as a co-activator of Oct4 in a regulatory feedback loop. In one study was demonstrated 
that these lncRNAs are not merely controlled by mESC transcription factors, but they 
themselves regulate developmental state(Sheik Mohamed, 2010 #195). We analyzed the 
similarity of MIAT sequence of human and Gomafu of mouse that supposed to be 
participated in the same feedback loop with Oct4, and demonstrate only ∽200bp 
resemblances in  these two long non coding RNA with more that 9kb length. However  the 
mechanisms by which MIAT and Oct4 feedback loop exert their impact remain unknown 
but worthy of future studies. Our study was also demonstrated concordance impression of 
the cancerous cellular features like apoptosis and cell viability after knockdown of either 
Oct4 or MIAT, that also presented a unique results to our knowledge. The results  showed 
that lncRNA MIAT RNAi induced apoptosis corresponding to negative control treated 
cells. Consistently the number of viable cells decreased. In addition, oct4 knockdown leads 
significant specific effects on number of viable cells and cells went to programmed death. 
The observation that existence differences in apoptosis and viability are consequences of 
Oct4 knockdown was proved by Real Time PCR on harvested cells. 
Our findings elucidate strong associations between lncRNA MIAT and a life threatening  
human diseases as leukemia. It also should help to explain the mechanisms by which 
lncRNAs MIAT can function as a modulator of pluripotency. Such future studies of 
transcription factors and their lncRNA targets should expand our grasp of regulatory 
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networks in which MIAT plays a role and potentially facilitates the derivation of rational 
therapeutic interventions and transfers lncRNA research to clinical oncology.  
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